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Chapter 1 
 
1.1 General introduction 
 
Proteins are large biological molecules that control most vital cellular 
functions. They consist of one or more chains of amino acids in an order 
determined by the base sequence of nucleotides in the DNA coding for the 
protein. Thanks to the information from the genetic code and according to the 
energy landscape, proteins fold into their correct three-dimensional structures 
and exert their specific function. The correct fold of large portion of the 
structure is generally related to specific protein functions and when any even 
small alterations occur, it is possible to observe a decrease, an increase or a 
drastic change in the protein function. In several cases alterations at the 
amino acid level can influence the conformational rearrangement, the 
function or the binding properties of a given protein. On this premise, 
knowledge on protein structure-function relationships can be crucial in 
finding the molecular basis for hereditary diseases and in predicting protein 
function from structure and vice versa. Therefore, the study of structure-
function relationships is really important nowadays to better understand 
several diseases at their molecular level. In particular, this kind of approach 
seems to be relevant in cancer research considering that several somatic 
variants resulting from alterations at the amino acid level have been detected 
in cancer genome for several proteins. The analysis of this kind of alterations 
is key to understand the genetic bases of disease progression, patient survival 
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and also response to therapy. Since knowledge of protein function in health 
and disease is essential to identify new and more specific cures for different 
diseases and to design pharmacologically active and more selective drugs, the 
information resulting from the analysis of somatic mutations found in cancer 
tissues can improve the available therapies and create new and more specific 
ones suggesting that precision and personalized medicine is not anymore a 
daydream. 
 
1.2 Single nucleotide variants 
 
The human genome, which consists of over 3 billion base pairs, has 
remained well conserved throughout evolution, in fact it is at least 99.5 % 
identical between any two humans on the planet [Levy S et al, 2007]. Modern 
genomic sequence analysis have revealed that it is more complex, diverse, 
and dynamic than previously thought, with possible genetic variations in the 
range from 0.1 % to 0.4 % [Jorde LB et al, 2004]. Sequence variations at the 
amino acid level may influence the conformation, function or binding 
properties of a given protein [Bhattacharya R et al, 2017]. When sequence 
changes occur, even in non-protein coding regions of the DNA, the 
consequent alteration in the human genome may cause or just be linked to a 
specific disease.  
In the last decades, several studies have focused their attention on protein 
variants and their relationship with rare, mendelian genetic diseases and some 
authors have recently hypothesized that the common variants may contribute 
significantly to genetic risk for common disease [Lander ES et al, 1996; 
Risch N et al, 1996; Collins FS et al, 1997].  
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The most common genetic differences in the human genome are 
polymorphisms, generally defined as single base pair variations in DNA 
sequence that occur in at least 1% of the population. These differences are 
called single nucleotide polymorphisms (SNPs) and they are considered the 
most common genetic variations observed in humans [Collins FS, 1998] (The 
International HapMap Consortium 2003) [Shastry, 2002], since they occur, 
on the average, once every 300–400 base pairs [Kruglyak and Nickerson, 
2001] in contrast with other types of polymorphisms (for example, 
differences in copy number, insertions, deletions, duplications, and 
rearrangements) that also occur, but much less frequently. Some of them are 
located within the coding or regulatory regions of genes but, considering that 
only about 5% of the human genome codes for the production of proteins 
(The International Human Genome Sequencing Consortium 2001), most 
single nucleotide mutations may fall in the non-coding regions of genes or in 
the intergenic regions. Point mutations within a coding sequence are of 
particular interest because they can cause qualitative and quantitative changes 
in gene expression, RNA splicing, protein translation, or gene function. 
Coding SNPs, especially nonsynonymous coding SNPs (nsSNPs), induce 
changes at the amino acid level of the polypeptide sequence of the protein 
generating protein variants with single amino acid substitution (nsSNVs), 
also referred to as missense mutations, that may present structural and/or 
functional alterations [Zhou et al, 2010].  
Only in the last years, millions of human SNVs have been identified, and 
these variants could be strongly correlated with phenotypic variations of 
traits/diseases [Cao et al, 2017]. It has been reported that nearly 30% of the 
nsSNVs are predicted to affect the protein function  [Chasman and Adams, 
2001; Ng and Henikoff, 2002; Ramensky et al, 2002]. Several nsSNVs have 
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been found neutral or with no effect on human health, but many nsSNVs 
have been linked to many diseases or may be responsible for individual 
susceptibility to contract diseases. 
In the last years, several sequencing initiatives [Hudson et al, 2012; 
Stratton et al, 2012] have deeply contributed to the implementation of 
information about nsSNVs detected in humans and many databases are  
nowaday available, listing  human SNVs and their effects, such as dbSNP 
(Single Nucleotide Polymorphism database) [Sherry et al, 2001], SAAPdb 
[Hurst et al, 2009] or SNPdbe [Schaefer et al, 2012]. Since genetic variation 
in the human genome is an emerging resource for studying cancer and other 
diseases [Mueller et al, 2015; Kunz et al, 2016, Zang et al, 2016, Didonna et 
al, 2015], in the last years databases like Online Mendelian Inheritance in 
Man (OMIM) [Hamosh a et al, 2005] and COSMIC [Forbes et al, 2010], that 
contribute to catalogue nsSNVs found in pathological tissues, have been 
created. Even if there is a huge amount of SNVs deposited in public platform, 
only a small proportion of them are functional polymorphisms that contribute 
to disease phenotypes [Tabor et al, 2002; Yuan et al, 2006]. Recently a new 
important database, named Pan-Cancer Atlas (https://www.cell.com/pb-
assets/consortium/pancanceratlas/pancani3/index.html), is available and 
catalogues the nsSNVs found in cancer tissues in the Genomic Data 
Commons (https://portal.gdc.cancer.gov/).      
Given the high potentiality of knowledge about the relationship 
between structure-function changes observed in nsSNVs and diseases, it is 
noteworthy that this field is extensively expanding in cancer research since 
several somatic mutations that have been identified in cancer tissues are 
nsSNVs. Until now a huge dataset has been generated and made available. A 
stumbling-block is represented by the fact that no tumor genome has been 
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completely characterized but the advances in high throughput technologies 
and the declining costs of high-throughput sequencing are transforming our 
understanding of cancer and will allow us to generate a comprehensive map 
of polymorphisms distributed over the entire genome that will be helpful to 
identify new and more appropriate therapies and to make effort in drug 
discovery. 
 
1.3 Overview of possible effects induced by 
single amino acid substitution 
 
Single amino acid substitutions can be beneficial, adding new 
functionality and increasing the fitness of the cells or deleterious, damaging 
the protein, causing destabilization of the protein structure or reducing its 
functional activity because of the disruption of a site that is directly involved 
in the function of the protein and thereby contributing to disease phenotypes 
[Studer et al, 2013]. Usually, change in amino acids with similar size and 
physico-chemical properties (e.g. substitution from leucine to valine) has a 
mild effect. Similarly, if the point mutation disrupts secondary structure 
elements (e.g. substitution to proline in alpha helix region) such mutation 
usually may affect whole protein structure and function. Thus nsSNVs can 
potentially affect the function of the cell in a variety of ways. 
The most important consequence of point mutations in different types 
of functional sites can be either the increase or the decrease of protein 
activity. The most dramatic effects have been detected when point mutations 
occur in the active sites of enzymes or in the binding pockets of receptors 
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[Stevanin et al, 2004; Yamada et al, 2006]. Considering that enzymes 
catalyze biochemical reactions not only thanks to catalytic residues, but also 
with several surrounding residues important for ensuring proper attachment 
of the substrates and cofactors to the active site cavity (binding sites 
residues), mutations that occur on the residues located in the neighborhood of 
the active site can influence the activity [Zhang et al, 2001; Takamiya et al, 
2002; Zhang et al, 2010]. In the human population, 25% of the known 
nsSNVs significantly affect protein function in vivo [Yue and Moult, 2006]. 
It has been reported that in most cases nsSNVs lead to loss-of-function (LOF) 
generally due to perturbation of the active site of the enzyme or of its global 
structure [Kucukkal et al, 2015] or to a reduction of the thermodynamic 
stability of the protein leading to a shift of the folding equilibrium toward the 
nonfunctional unfolded state, possibly coupled to irreversible aggregation 
(thermal instability) and/or degradation by cellular quality control [Yue et al, 
2005; Casadio et al, 2011; Shi et al, 2011; Stefl et al, 2013; Petukh et al, 
2015]. Sometimes, but not commonly, nsSNVs can result in a protein that 
still functions, even if in a “non-canonical” way, as evident in the so-called 
gain-of-function (GOF) mutants that generally include oncogenic mutations 
in proteins such as the Ras GTPase and the epidermal growth factor receptor 
family of tyrosine kinases, which often drive cancer tumor cell development 
and proliferation [Schubbert et al, 2007; Arteaga et al, 2014]. 
The occurrence of a mutational event can generate a protein variant 
that perturbs conformational constraints of the native protein (e.g., 
substituting a small side chain residue to a large one and vice versa, resulting 
in backbone strain or overpacking) or have physicochemical effects 
(substitutions between hydrophilic residues and hydrophobic residues, burial 
of charged residues, the disruption of hydrogen bonds, loss of hydrogen 
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bonds, of S–S bonds) [Shirley et al, 1992], leading to considerable alterations 
of the stability of the native protein [de Cristofaro et al, 2006; Koukouritaki 
et al, 2007; Ode et al, 2007]. Protein stability is a key characteristic of a 
functional protein [Wang and Moult 2001; Zhang et al, 2001; Ramensky et 
al, 2002; Wang and Moult 2003; Capriotti et al, 2005; Karchin et al, 2005; 
Ye et al, 2006; Zhang et al, 2010]. It is known that a single base DNA 
substitution may result in alteration of stability of the corresponding native 
protein [Wang and Moult, 2001; Yue et al, 2005] and that about 80% of 
missense mutations associated with disease affects the stability of proteins by 
several kcal∙mol−1 [Wang and Moult, 2001]. Generally, a nsSNV can have 
destabilizing or stabilizing effects: most frequently, missense mutations lead 
to a destabilization of the protein stability by making it susceptible to 
proteolysis or by changing the thermal inactivation temperature. The impact 
of protein destabilization can be observed in several proteins involved in 
many neurodegenerative diseases, such as Parkinson's disease [Lin et al, 
2008; Morais et al, 2009; Nuytemans et al, 2010] or in cancer, where 
destabilizing mutations in the core of the protein lead to an inactivation of 
many tumor suppressors [Stehr et al, 2011]. An amino acid substitution can 
occur at a position critical for the folding of the protein destabilizing it and/or 
stabilizing a misfolded state [Valastyan and Lindquist, 2014]. The 
importance of the correct folding of a protein is clear if we consider the 
hundreds of diseases associated with many misfolded proteins [Dobson, 
2003; Thusberg and Vihinen, 2009; Groenendyk et al, 2010; Valastyan and 
Lindquist, 2014]. 
 Several investigations have been addressed to better elucidate how 
missense variants can induce minimal or significant alterations on the protein 
flexibility [Young et al, 2001; Zhang et al, 2010; Karplus and Kuriyan, 2005] 
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considering that the conformational flexibility of a protein is crucial for its 
correct folding, for the binding with partners and for its function. The 
presence of a point mutation, by altering the protein flexibility, can affect 
protein aggregation propensity. This is considered a hallmark of some 
neurodegenerative diseases, like Alzheimer‟s disease (AD), Parkinson‟s 
disease (PD), Huntington‟s disease (HD), amyotrophic lateral sclerosis (ALS) 
and prion diseases [Guijarro et al, 1998; Chiti et al, 1999; Fandrich et al, 
2001; Chiti et al, 2003; Bucciantini et al, 2004; Harris and True 2006; Keage 
et al, 2009; Khemtemourian et al, 2008; Robinson, 2008; Yankner and Lu 
2009] and for this reason research on protein misfolding and aggregation is 
progressively gaining increasing attention. The general mechanism by which 
nsSNVs promote these diseases is the promotion of toxic protein aggregation 
[Calamini and Morimoto, 2012; Knowles et al, 2014; Valastyan and 
Lindquist, 2014] triggered by the destabilization and unfolding of the native 
protein structure, which exposes aggregation-prone regions previously buried 
inside the structure.  
Approximately 60% of disease-associated nsSNVs induce a 
perturbation in the binding site of the protein, expecially if the point mutation 
affects residue located on protein-protein interface [Schuster-Bockler and 
Batemen, 2008; Teng et al, 2009; David et al, 2012], and may lead to changes 
in the interactions with partners (activators, repressors or substrates) and in 
the binding specificity [Kohler et al, 2008; Wu et al, 2008; Bauer-Mehren et 
al, 2009; Vanunu et al, 2010; Barabàsi et al, 2011]. Many of these mutations 
induce significant perturbations that result in complete loss of interactions or 
complete abolishment of the function, generally leading to diseases [Wang et 
al, 2012; Sahni et al, 2015].  
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The impact of single amino acid substitutions on protein stability has 
been investigated by theoretical and experimental approaches [Bross et al, 
1999; Wang and Moult, 2001; Ferrer-Costa et al, 2002; Steward et al, 2003; 
Yue et al, 2005; Scheraga et al, 2007; Dill et al, 2008; Fersht, 2008]. In 
general, the experimental studies are relatively limited due to the cost and 
time needed for the entire process which often includes mutagenesis, protein 
expression and purification, followed by thermal or chemical unfolding.  
 
1.4 How can you study the impact of single 
point mutations on the protein? 
 
 Single point mutations can occur between different individuals of the 
same species. These mutations can lead to a protein without any changes in 
its amino acid sequence (synonymous SNVs (sSNVs)), insert a stop codon or 
generate a protein variant with an amino acid change (nsSNVs). Even if most 
SNVs are neutral or have no effect on human health and embryonic 
development [Kimura M, 1983; Wang Z, Moult J, 2001], a large number of 
nsSNVs have been associated with diseases [Wang Z et al, 2001]. Due to the 
complexity of human biology, the association of a nsSNV with a complex 
phenotype is still a problem and methods that target understanding the effects 
of missense mutations on various sequence, structural and functional features 
are progressively implemented in the hope of deciphering the phenotype–
genotype relations [Stanley et al, 2013; Yates and Sternberg 2013; Kucukkal 
et al, 2014].  
 Nowadays bioinformatics tools can be really helpful to filter large 
datasets of genetic variation and in the last decades good computational 
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methods have been developed to predict the effect of nsSNVs and their 
pathogenicity in order to predict the experimentally observed effects for 
disease-related variants [Hecht et al, 2013]. These methods are based on 
implemented computational algorithms that allow the evaluation and analysis 
of mutations as a function of their pathological consequence [Balu and 
Purohit, 2013; Kamaraj and Purohit, 2013; Kamaraj et al, 2013; Kumar et al, 
2013] giving us the possibility to distinguish the non-significant SNVs from 
the ones that might produce major disease associated consequences. 
Computational methods such as SIFT [Sim et al, 2012], Polyphen-2 
[Adzhubei I. et al, 2013], StSNP [Uzun et al, 2007], Bongo [Cheng et al, 
2008], Condel [Ng and Henikoff, 2006; Gonzalez-Perez and Lopez-Bigas, 
2011] and MAPP [Stone E.A. et al, 2005] classify SNVs according to neutral, 
negative or positive effects on the structure or function of a protein, while 
different computational methods, such as FoldX [Schymkowitz et al, 2005], 
PoPMuSiC [Dehouck et al, 2011], CUPSAT [Parthiban et al, 2006], Rosetta 
[Leaver-Fay et al, 2011] I-Mutant [Capriotti et al, 2005] or INPS (a predictor 
of the Impact of Non-synonymous-variations on Protein Stability) have also 
been developed to classify a single amino acid substitution according to its 
effect on the protein stability by comparing wild-type with mutated proteins, 
and predicting the variation of protein stability (∆∆G) of the mutation. 
However these methods are generally based on a single folded structure, but 
the native state of a protein is not unique, thus it is important to consider the 
entire ensemble of the protein conformers in dynamic equilibrium.  
A deeper understanding of the effect of a point mutation on the protein 
structural, physical and chemical properties requires the utilization of several 
techniques: only a combination of predictive analysis and experimental 
procedures can give us a whole picture regarding the consequences of 
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missense mutations on protein. Since in the last years the accepted paradigm 
that proteins can tolerate nearly any amino acid substitution has been 
replaced by the awareness of deleterious effects of mutations, especially on 
the thermodynamic and kinetic stability of protein, several methods have 
been developed to catalogue the nsSNVs that affect the stability and function 
of the protein [Ng and Henikoff, 2006; Yue and Moult, 2006]. In order to 
combine the results of the various tools, consensus predictors have been 
developed to allow comparison between methods that use different analytical 
approaches [Vendruscolo et al, 2003; Bendl et al, 2014]. 
 One useful method largely used to provide information about the 
conformational changes that a mutated protein may undergo under various 
conditions is the molecular dynamics simulation (MD) leading to a 
systematic evaluation of molecular properties in dynamic molecular systems. 
Using specific algorithms it is possible to assess the potential impact of 
variants within the protein revealing the possible various mechanisms by 
which variants may lead to functional alteration. Some of them can be 
revealed energetically, others structurally or dynamically analyzing the 
dynamic behaviour of proteins [Zimmermann MT et al, 2017]. 
The importance of a combination of experimental studies with molecular 
dynamics simulations allow us to highlight several experimental procedures 
that can be used to reveal the structural and functional effects of single amino 
acid changes in proteins owing nsSNVs. Of particular interest are 
experimental methods that provide 3D structures of genetic variant proteins 
revealing atomic-level structural details with which it‟s possible to analyze 
the structural differences caused by the variation at the DNA level. X-ray 
Diffraction, solution Nuclear Magnetic Resonance or Electron Microscopy 
contribute to implement the PDB archive [Rose PW et al, 2015]. Even if the 
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availability of the 3D structure of a gene product represents the most 
informative source of data that can explain what is able to cause a particular 
phenotype, most studies that analyze the relationship between point 
mutations and experimentally observed 3D protein structure published to date 
have been restricted to individual proteins or single diseases. There is a 
paucity of quantitative analyses of the consequences of SNVs on 3D protein 
structure going beyond the realm of prediction [Arodź and Płonka, 2012], 
even if tools that incorporate structural information when making predictions 
have been implemented [Brown DK Bishop ÖT, 2017]: an excellent 
communication between bioinformatics and biomolecular scientists is 
requested to increase the amount of data about genetic variants and 
phenotype.  
Since several nsSNVs associated with different diseases can affect the 
stability of the native protein [Wang and Moult, 2001], protein folding 
analysis and stability measurements may be useful for the study of disease-
associated processes [Adhikari et al, 2015]. With this purpose mutagenesis 
can be used to obtain mutated proteins and followed by protein expression 
and purification steps in order to obtain a pure protein product that can be 
analyzed by thermal or chemical unfolding to determine the difference of 
Gibbs free energy value (∆G) between the wild-type and the mutated 
proteins. Several forces contribute to the stabilization of the folding state of a 
protein, expecially hydrogen bonding, hydrophobic contacts between the 
buried side chains in the interior of the molecule out of contact with water, 
and the formation of intramolecular contacts between side chains [Eswar and 
Ramakrishnan 2000]. In their stable state, proteins are marginally stable, 
between −3 and −10 kcal∙mol−1 [Taverna and Goldstein, 2002]. They can 
tolerate some destabilization within a narrow range [Bershtein et al, 2006; 
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Goldstein, 2011] but when this range is overshot a pathological condition can 
occur. Point mutations may add energy (i.e. more than +2 kcal∙mol−1) to the 
folded state and destabilize the equilibrium between the native state and the 
unfolded one, making the protein more likely to aggregate in its unfolded 
form: this is a crucial event in some diseases characterized by unfolded 
aggregates of proteins [Yue et al, 2005]. However, in some cases a mutation 
removes energy from the folded state (i.e. less than +2 kcal∙mol−1) and 
stabilizes it making the protein too rigid and so non-functional. Most of the 
disease-causing mutations were found to be destabilizing [Pasquo et al, 2012; 
Grothe et al, 2013; Khan et al, 2013] and, in particular, the degree of 
destabilization was found to be elevated for mutations that introduce drastic 
changes such as charged to neutral, relatively rigid to relatively flexible, or 
aromatic to aliphatic mutation types. 
Considering the plausible alterations in the folding process caused by point 
mutations, it is not surprising that experimental studies about protein folding 
and stability are needed. 
Equilibrium studies allow to understand the cooperativity of the folding 
process and can be used to evaluate the conformational stability. Usually 
denaturation is studied monitoring changes in secondary or tertiary structural 
elements in protein, by means of circular dichroism or fluorescence 
spectroscopy, when different concentrations of a chemical denaturant agent 
are used to induce the denaturation process. Urea and guanidine 
hydrochloride are the most common chemical denaturant agents used, 
because it is well known that the interaction of urea or guanidine 
hydrochloride with the constituent groups of proteins is more favorable than 
the interaction of those groups with water [Tanford C, 1970]. Denaturants 
alter the equilibrium between the native (N) and the denatured (D) states and 
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the free energy of unfolding reaction is given by: G = RT ln ([D]/[N]), 
where [D] and [N] are the concentrations of protein in the denatured and 
native state, respectively.  
Thermal denaturation experiments can also be performed due to the large 
amount of information that they can give about the denaturation process of a 
given protein. In particular, calculation of the Tm plotting the first derivative 
of the molar ellipticity values at around 222 nm, where helices are known to 
give their spectral signal, as a function of temperature, it‟s possible to 
compare the transition curves of the wild-type and of the mutated proteins 
looking at the midpoint of the denaturation process. 
Furthermore, the folding process of a given protein can be analyzed by 
following the kinetics of unfolding that allow to understand the protein 
dynamics and provide information about the folding pathway. Kinetic studies 
are performed by altering the equilibrium of the system introducing a 
perturbation, such as mixing two solutions with different urea concentrations 
or increasing rapidly the temperature of the sample, and evaluating how the 
system relaxes to a new equilibrium. The relaxation process can be estimated 
by following the variation of an optical probe with time, such as the 
fluorescence of the aromatic residue. 
 
1.5 nsSNVs and cancer 
 
Cancer is an important health problem worldwide, considered as one 
of the most frequent causes of death. It is a genetic disease caused by changes 
of genes that control the way in which cells function allowing them to grow 
out of control and become invasive. These kind of abnormalities have been 
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detected studying cancer genomes, however large-scale research studies are 
still needed to characterize some tumour types that have not been deeply 
characterized. Furthermore it is important to take into consideration that each 
cancer type has a unique combination of genetic changes in different patients 
that can be inherited from the parents or can be related to the adoption of 
unhealthy lifestyle, including smoking, drinking, physical inactivity and 
„„westernized‟‟ diets [Hua et al, 2014]. In fact, several types of cancer can be 
caused by environmental factor exposures that include substances, such as 
the chemicals in tobacco smoke, and radiation, such as ultraviolet rays from 
the sun, which can lead to cancer by inducing DNA damage [Levi et al, 
1999]. In addition, in cancer cells genetic variation occurs with an increased 
frequency due to the uncontrolled proliferation and the compromised DNA 
integrity. 
Since the mechanisms of cancer cells at their molecular level have not 
been identified, new technologies and the knowledge gained from previous 
genomic studies could be used to define the full set of alterations to DNA and 
RNA in many cancers. It can be really useful to set studies that compare 
genomic information from tumours and normal tissue from the same patient 
in order to allow researchers to discover genomic changes that may drive 
cancer. Another possibility is to expand the current use of genomic methods 
to investigate the molecular basis of clinical phenotypes in order to identify 
genetic changes that may distinguish aggressive cancers from indolent ones 
or to study the molecular basis of response to a given therapy, as well as 
mechanisms of resistance to treatment. 
Nowadays the National Cancer Institute (NCI) is working to analyze 
the DNA and RNA of cancer cells using advanced technologies such as next-
generation DNA sequencing. Using multiple genomic techniques the 
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landscape of the cancer genome is mapped in order to discover new changes 
linked to disease. In particular, a collaboration between NCI and the National 
Human Genome Research Institute (NHGRI), and Therapeutically 
Applicable Research to Generate Effective Treatments (TARGET), named 
The Cancer Genome Atlas (TCGA), have characterized thousands of 
genomes and matched normal samples making available a collection of cross-
cancer analyses delving into overarching themes on cancer, including cell-of-
origin patterns, oncogenic processes and signaling pathways. 
It is clear that in cancer research genetic susceptibility plays an 
important role: genome-wide association studies (GWAS) have been 
conducted in large cohorts of patients allowing us to say that cancer can be 
considered a genetic disease sometimes caused by a single or few 
catastrophic somatic mutations that are responsible for cellular 
transformation [Zhang CZ et al, 2015], and sometimes caused by a 
combination of several genomic alterations that work together to promote 
cancer. Many of the identified causal genetic changes are related to the SNV 
that derives from a substitution of one base pair in DNA and that can initiate 
the cascades of downstream signaling and eventually transforms the cellular 
phenotype from normal to malignant [Hyeonju S et al, 2017]. These 
mutations represent novel targets for therapeutic intervention in this 
otherwise incurable disease. 
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1.5.1 nsSNVs and cancer: the experimental 
system 
 
 Although nsSNVs are theoretically expected in tumours, as it has 
been shown in the previous section, they can occur in mostly random manner 
across the genome or they can be significantly biased toward a specific codon 
transition [Hyeonju S et al, 2017]. Furthermore, it is not easy to characterize 
all the nsSNVs found in cancer tissues by an experimental point of view, due 
to the large amount of variants identified in several proteins involved in 
different pathways and to the cost and time required for the experiments. 
However, since structural and functional analysis of nsSNVs in the DNA 
sequences of humans may help to predict an individual‟s response to certain 
drugs, susceptibility to environmental factors, and risk of developing 
particular diseases [Johnson et al, 2008; Zhou et al, 2010], during the last 
years we focus our attention on the characterization of nsSNVs of different 
proteins involved in the regulation of cell metabolism and in the response of 
DNA damages. 
In particular, during my PhD I carried on a biochemical characterization of 
nsSNVs that have been detected in different types of cancer of three proteins 
involved in the regulation of cell metabolism, such as the Phosphoglycerate 
kinase 1 (PGK1) and the human Frataxin (hFXN), or in the response of DNA 
damages, such as the Poly (ADP-ribose) polymerase 3 (PARP3). Using 
structural and functional analysis our aim was to investigate any possible 
correlations between alteration on protein structure, function or stability 
caused by single amino acid substitutions and cancer. Furthermore in order to 
present a detailed discussion about this issue, in this thesis I‟m going to 
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combine the results obtained during my PhD with those obtained for variants 
of other proteins studied by our group in the last years: Bromodomains 
(BRDs), Peroxisome Proliferator-Activated Receptor  (PPAR), 
Serine/threonine-protein kinase pim-1 (Pim-1) and Protein tyrosine 
phosphatase  (PTP) in order to present a systematic and comparative 
analysis of properties of protein variants caused by single amino acid 
substitutions. 
 
1.5.1i Phosphoglycerate kinase 1 
 
Tumors reprogram pathways of nutrient acquisition and metabolism 
to meet the bioenergetic, biosynthetic and redox demands of malignant cells: 
altered metabolic activity supports anabolic growth during nutrient replete 
conditions, catabolism increases to support cell survival during nutrient 
limitation, and fortification of redox homeostatic systems to counteract the 
metabolic effects of oncogene activation, tumor suppressor loss, and other 
stresses [Boroughs L.K. et al, 2015].  
The greater example of a reprogrammed metabolic pathway in cancer is the 
Warburg effect or aerobic glycolysis [Lunt S.Y. et al, 2011]. Glycolysis is a 
physiological response to hypoxia in normal tissues, and Otto Warburg in the 
1920s observed that cancer cells are able to adapt to survive in difficult 
conditions, like for example in O2 deficiency, through a reprogramming of 
their metabolism according to their requirements [Bertout J.A. et al, 2008]. 
Phosphoglycerate kinase (PGK) (EC 2.7.2.3) is an essential glycolytic 
enzyme for all living organisms. It catalyzes the reversible phosphotransfer 
reaction from 1,3-bisphosphoglycerate (1,3-BPG) to MgADP to produce 3-
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phosphoglycerate (3-PG) and MgATP, an important ATP-generating step in 
glycolysis [Beutler E., 2007]. By controlling ATP and 3-PG levels, PGK 
plays an important role in coordinating energy production with biosynthesis 
and redox balance. PGK is a typical hinge-bending monomeric enzyme of 
417 amino acids with an apparent molecular mass of approximately 45 kDa. 
It is characterized of two domains of equal size, the N- and C-terminal 
domains. The N-terminal domain binds 3-PG or 1,3-BPG, whereas the C-
terminal domain binds MgADP or MgATP. The two domains are separated 
by a deep cleft and linked by two alpha-helices (α-helix 7 and α-helix 14) 
[Vas et al, 2010; Palmai et al, 2009]. During the catalytic cycle this flexible 
hinge region allows the two domains to approach involving a large number of 
conformational rearrangements: in the open form the enzyme binds the 
substrates while in the closed form the enzyme performs the transfer of the 
phosphoryl group and it exerts its catalytic activity [Vas et al, 2010]. 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1 Phosphoglycerate kinase 1 (PDB code: 2XE7, open conformation) PGK1 is 
composed by two domains of equal size, the N- and C-terminal domains (violet and green, 
MgATP 
3-PG 
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respectively), connected  by a hinge region (blue). The N-terminal domain binds 3-PG or 
1,3-BPG, whereas the C-terminal domain binds MgADP or MgATP.  
 
Two human phosphoglycerate kinase isoenzymes have been identified: 
PGK1 and PGK2. They are characterized by distinctive tissue localization 
and encoded by two distinct genes [Willard et al, 1985; McCarrey et al, 
1987]. PGK1 is ubiquitously expressed in all somatic cells while PGK2, also 
known as testis form, is unique to meiotic/postmeiotic spermatogenic cells. 
Interestingly, similar to many other glycolytic enzymes, human PGK1 was 
found implicated not only in the glycolytic pathway infact, in addition to its 
metabolic function, it may play different roles. In mammal cell nuclei, for 
example, this enzyme participates in the DNA replication and repair [Jindal 
et al, 1990]; it can also phosphorylate L-nucleoside analogues used in 
antiviral and anticancer therapies [Krishnan et al, 2003; Gallois-Montbrun et 
al, 2004; Gondeau et al, 2008].  
Furthermore, this enzyme may be surprisingly secreted by tumors in the 
extracellular environment where it exhibits thiol reductase activity on 
plasmin that permits the cleavage of plasminogen in order to generate the 
vascular inhibitor angiostatin [Lay et al, 2000]. Thus the enzyme has been 
suggested to be an important negative regulator of the angiogenic process 
that is essential for tumour and metastatic growth [Shichijo et al, 2004; Wang 
et al, 2007]. It has been found that PGK1 regulates angiogenesis by 
generating angiostatin and by reducing the secretion of the proangiogenic 
cytokines VEGF and IL-8. CXCR4 signaling regulates PGK1 expression. At 
sites of high CXCL12 production, PGK1 secretion is inhibited by the 
CXCL12/CXCR4 axis. Thus, CXCL12 signaling through CXCR4 generates 
an „angiogenic switch‟ necessary for metastatic growth. Together, these data 
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further show that CXCL12/CXCR4 chemokine axis and PGK1 represent at 
least one of the critical events necessary for metastasis of prostate cancer as 
well as a mechanism for a proangiogenic switch to promote tumor growth 
[Wang et al, 2007].  
In addition, under hypoxic conditions, PGK1 may translocate from cytoplasm 
to mitochondrion where it may act as a protein kinase and phosphorylate 
different protein substrates [Li et al., 2016]. In particular, under hypoxic 
stress, ERK activation-dependent mitochondrial translocation of a small 
portion of cytosolic PGK1 have been observed [Li X. et al, 2016]. Once 
activated, ERK1/2 phosphorylates PGK1 at Ser203 allowing the recruitment 
of the PIN1 prolyl isomerase and leading to isomerisation of the Ser203. 
Pro204 bond and the subsequent exposed PGK1 pre-sequence (38-QRIKAA-
43) on its surface is recognized by the mitochondrial translocase of the outer 
membrane complex, leading to the translocation of PGK1 into the 
mitochondria. Here, PGK1 acts as a protein kinase, interacts with and directly 
phosphorylates pyruvate dehydrogenase kinase isozyme 1 (PDHK1) at 
Thr338 using ATP as a phosphate donor. This phosphorylation activates 
PDHK1 and enhances PDHK1- mediated pyruvate dehydrogenase E1 a 
phosphorylation at Ser293, which inactivates the pyruvate dehydrogenase 
complex preventing the conversion of pyruvate and coenzymeA (CoA) to 
acetyl-CoA and CO2 in the mitochondria. This phosphorylation inhibits 
mitochondrial pyruvate metabolism and ROS production and enhances 
lactate production, thereby promoting tumour development [Xinjian et al, 
2016]. Recently, the protein kinase activity of PGK1 has been related to 
initiation of autophagy [Qian et al., 2017]. 
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Fig. 1.2 Mechanism of Mitochondrial PGK1-Coordinated Glycolysis and TCA Cycle in 
Tumorigenesis [Xinjian Li et al, 2006; doi:10.1016/j.molcel.2016.02.009]. 
 
PGK1 is regulated by hypoxia-induced factor-1ɑ (HIF-1ɑ), the most 
important factor involved in the cellular response to hypoxia (Wang et al, 
2007). Several solid tumors exhibit an increased expression of glycolytic 
enzymes such as PGK1 to generate ATP in hypoxic conditions. Elevated 
levels of PGK1 protein have been detected in the serum of patients with 
pancreatic cancer (Hwang et al, 2006) and in breast cancer tissues compared 
with normal tissues (Kabbage et al, 2008) and this suggests a plausible 
activity of the enzyme as a biomarker for cancer. 
A great number of mutations of the PGK1 gene have been so far 
identified: most of them are related to the X-linked human PGK1 Deficiency 
(OMIM entry 311800) [Chiarelli et al, 2012]. PGK1 Deficiency is a genetic 
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disease that has been found in ∼40 patients, and ∼20 different mutations have 
been shown to be disease-causing mutations. Approximately 80% of the 
mutations cause single amino acid substitutions or small deletions [Fermo et 
al, 2012]. PGK1 deficient patients show heterogeneous phenotypes including 
chronic nonspherocytic hemolytic anemia, neurological dysfunctions, and 
myopathies, even though the presence of all three types of clinical signs in 
the same patient is rare.  
In addition, several somatic mutations of PGK1 have been exclusively 
identified in different cancer types, as reported in COSMIC (Catalogue of 
Somatic Mutations in Cancer) (http://cancer.sanger.ac.uk/cosmic) [Forbes et 
al., 2011]. The role of PGK1 variants in cancer is not still clear, so this study 
would give a biochemical characterization of some PGK1 variants (R38M, 
R65W, G166D, M189I, A199V, V216F and F241S) found in cancer tissues 
and annotated in the COSMIC database [Forbes et al, 2010].  
 
1.5.1ii Human Frataxin (hFXN) 
 
 Several studies in the literature about cancer highlight the relationship 
between iron metabolism and carcinogenesis [Richardson D.R. et al. 2009; 
Torti S.V. 2011, 2013]. Iron is an inorganic element which is critical for cell 
proliferation and growth by incorporating into iron- or heme-containing 
enzymes. Since these enzymes are involved in respiratory complexes, DNA 
synthesis, cell cycle and detoxification processes, iron is essential in terms of 
cell replication, cellular metabolism and growth. Iron is not only fundamental 
for cell survival but it can be related to carcinogenesis because, beside the 
effects mentioned above, iron can create reactive oxygen species (ROS) by 
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participating in Fenton reaction where hydroxyl radical is produced: ROS can 
damage DNA and be mutagenic.  
Frataxin (FXN) is a small highly conserved mitochondrial protein 
ubiquitously expressed in prokaryotes and eukaryotes [Adinolfi et al, 2002; 
Gibbson et al, 1996] that plays an important role in Fe-S cluster biosynthesis 
and iron and heme metabolism [Muhlenhoff et al, 2002; Che net al, 2002; 
Busi et al, 2006]. Sequence alignment of the frataxin family shows two 
distinct regions: an N-terminal region of 70-90 residues completely absent in 
prokaryotes and poorly conserved in eukaryotes with typical unfolded 
features [Huynen MA et al, 2001] and a highly conserved C-terminal region 
of 100-120 residues with a sequence identity of about 25% and similarity 
around 40-70% indicating that this part of the protein is functionally 
important [Pastore A et al, 2013]. Frataxin is nuclear encoded, expressed in 
the cytoplasm and imported in the mitochondrion through an import signal 
contained in the N-terminal region of the protein. In fact, human frataxin 
(hFXN) is synthesized as a precursor of 210 amino acids and imported into 
the mitochondrion where the mitochondrial processing peptidase operates 
several cleavage processes that remove the N-terminal region and allow the 
formation of the mature form of the protein [Koutnikova H et al, 1998; 
Condò I et al, 2007; Schmucker S et al, 2008].  
The mature protein consists of amino acids 81–210 and has an apparent 
molecular mass of about 14 kDa [Campuzano et al, 1996]. The human 
isoform shows an α- β sandwich structure composed of two α-helices, which 
form one plane over five antiparallel β-strands, which form the second plane. 
Furthermore, two others β-strands intersect the two planes in order to achieve 
the overall structure [Bencze et al, 2006].  
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Fig. 1.3 Human Frataxin (PDB code: 1EKG) Globular structure of hFXN with two 
terminal α-helices which pack against a -sheet with 7 strands, giving a planar α- β sandwich 
structure motif. 
 
Several conserved acidic residues (Asp, Glu) are located between the 
first helix and the edge of the β 1-sheet gene rating a semi-conserved acidic 
ridge that generates a negatively charged surface (Fig. 1.4) that seems to be 
involved in iron binding and in binding with partners [Dhe-Paganon et al, 
2000]. Three tryptophans are also conserved even if the occurrence of this 
kind of residue is relatively low in proteins, suggesting that they could have 
an important structural and/or functional role.  
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Fig. 1.4 Molecular representation of the negatively charged surface of hFXN. This acidic 
region is located on the interface between 1 and the first 1 strand and seems to be 
involved in iron binding and in binding with partners.  
 
In mammals, frataxin is mainly espressed in tissues with a high 
metabolic rate, like neurons, heart, kidney and liver and normally activates 
mitochondrial iron-sulfur-cluster protein assembly complex, which is 
composed of the Nfs1 enzyme and the scaffold protein Isu [Gerber J et al, 
2003; Ramazzotti A et al, 2004]. These two proteins are, respectively, the 
cysteine desulfurase that converts cysteine to alanine and the transient 
scaffold protein on which the cluster assembles  [Bandyopadhyay S et al, 
2008; Py B et al, 2011]. 
The direct frataxin partner have been extensively studied: early genetic and 
biochemical studies were careful to generically indicate interaction between 
frataxin and the Nfs1/Isu complex [Gerber J et al. 2003; Ramazzotti A et al. 
2004], however later it was reported that human frataxin interact with Isu 
with high affinity and in an iron-dependent way [Cook JD et al. 2006; Bencze 
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KZ et al. 2007]; finally, independent works confirmed that hFXN interacts 
with a preformed complex composed of Nfs1, Isu and Isd11 in an iron-
independent fashion [Tsai and Barondeau 2010; and Schmucker S et al. 
2011].  
The notoriety of this protein is predominantly related to Friedreich 
ataxia (FRDA), an autosomal-recessively inherited disorder described for the 
first time in 1863 by Friedreich and with an incidence of 1:50000 in the 
European population. 95% of FRDA patients are homozygous for unstable 
guanine-adenine-adenine (GAA) expansions in the first intron of the frataxin 
gene (fxn) on the positive strand of chromosome 9q21.11 [Campuzano et al, 
1996], however another 5% of FA patients are compound heterozygotes with 
an expansion on one allele and conventional mutations on the other. At least 
15 missense point mutations have been reported [Cossée M et al, 1999; 
Labuda M et al, 1999; Musco G et al, 2000; Leidgens S et al, 2010; 
Schmucker S et al, 2011]. In vitro studies demonstrated that these variants 
(W155R, I154F, D122Y, G130V, N146K) retain a native fold under 
physiological conditions but have reduced thermodynamic stabilities and 
binding property of frataxin for its protein partners [Musco et al, 2000; 
Correira A et al, 2006, 2008]. The core syndrome is an early onset, slowly 
progressive ataxia associated with areflexia that appears during adolescence. 
Ataxia arises from combined afferent (peripheral sensory neuropathy plus 
spinal degeneration), cerebellar and sometimes also vestibular dysfunction. In 
addition to ataxia of stance and gait, patients develop appendicular and 
truncal ataxia. Dysarthria is another cerebellar feature present in 70% with 
abnormal pitch variation, loudness maintenance, breath support for speech, 
hypernasality and consonant imprecision due to laryngeal or velopharyngeal 
dysfunction [Folker  et al, 2010]. Cardiac involvement is also possible, with 
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left ventricular hypertrophy, paroxysmal or permanent supraventricular 
tachycardias [Bourke et al, 2011]. In 8 to 49% of the cases it‟s possible to see  
diabetes [Dürr  et al, 1996; Finocchiaro et al, 1988] with an usually late 
manifestation in the course of FRDA (mean 15 years after onset) [De 
Michele  et al, 1996]. The onset is often acute, sometimes with ketoacidosis 
[Bird et al, 1978]. The main event in the etiology of diabetes is the loss of 
pancreatic islet ß cells with concomitant decline of insulin secretion. The 
process is further aggravated by increased insulin requirements due to insulin 
resistance. Scoliosis is considered typical for FRDA. Its prevalence varies 
between 33 and 100% depending on the individual study [Harding et al, 
1981; Labelle et al, 1986]. Similarly, foot deformities (pes cavus, club foot, 
pes planus) may significantly interfere with mobility in 55 to 90% of patients. 
Severity does not depend on expansion size or age of onset, but is related to 
disease duration and age. 
Despite several studies have been performed until now on frataxin, the exact 
function of this protein is still unclear: in addition to its certain implication in 
iron homeostasis [Richardson et al, 2010], iron–sulfur cluster (ISC) 
biosynthesis [Stemmler ey al, 2010] and protection from oxidative stress and 
apoptosis [Condo et al, 2006], it seems that frataxin can be involved in 
several other functions.  
Frataxin is a protein required for cell survival since its complete 
knockout is lethal. This protein protects tumour cells against oxidative stress 
and apoptosis but also acts as a tumour suppressor [Guccini I et al, 2011] and, 
until now, the molecular bases of this apparent paradox are missing. 
Furthermore, conflicting results have been reported on the role of frataxin in 
cellular growth: both frataxin knockdown and frataxin overexpression were 
shown to impair cell growth [Stehling O et al, 2004; Thierbach R et al, 2005; 
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Schulz TJ et al, 2006]. Very little is known regarding the molecular 
regulation of frataxin expression: histone deacetylase inhibitors, 
erythropoietin, cisplatin, 3-nitropropionic acid and hemin increase levels of 
frataxin in vitro (Gottesfeld  et al, 2007). Moreover, transcription factors 
peroxisome proliferator-activated receptor gamma (Marmolino et al, 2009) 
and hypoxia-inducible factor-2 alpha (HIF-2a) (Oktay et al, 2007) positively 
regulate frataxin expression. It has been reported that frataxin overexpression 
can protect tumour cells from apoptosis but can also act as a tumour 
suppressor participating, by regulating p53 activation, in tumour adaptation 
to hypoxia, a critical feature associated with tumour growth and progression, 
thus suggesting that frataxin levels can influence tumour cell fate [Guccini I 
et al, 2011]. 
Furthermore, in several databases such as COSMIC database or 
ATLAS, several FXN variants have been reported suggesting that 
abnormalities in this highly conserved essential protein can be implicated in 
cancer onset and/or progression. This study would give a biochemical 
characterization of some FXN variants (D104G, A107V, F109L, Y123S, 
S161I, W173C, S181F and S202F) found in cancer tissues and annotated in 
the COSMIC database [Forbes et al, 2010].  
 
1.5.1iii Poly (ADP-ribose) polymerase 3 (PARP3) 
 
In addition to the accepted role for cell metabolism in cancer, it is 
well established that DNA-repair/DNA-damage pathways are important in 
cancer progression because dysregulation leads to higher levels of genomic 
instability, increased mutation rate, and enhanced intra-tumor heterogeneity 
[Burrel RA et al, 2013; Chae YKet al, 2016; Gavande NS et al, 2016]. 
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Mutations in DNA-repair genes can confer growth and survival advantages of 
cancer cells, therefore it can be interesting to improve knowledge about this 
important aspect of cancer biology because this might lead to the 
development of new targeted therapies in DNA-repair deficient cancers or 
even can improve the efficacy of existing therapies, such as PARP inhibitors. 
The biological roles of Poly (ADP-ribose) polymerase 3 (PARP3) are 
currently under investigation; however, several key reports indicate the 
integral roles of PARP3 in DNA damage repair responses [D‟Amours et al, 
1999; Ame et al, 2004], and thus it has been investigated as a novel target in 
oncology. 
PARP3 is an important member of the PARP family, also referred to 
as diphtheria toxin-like ADP-ribosyltransferases (ARTD), composed of 17 
members which all share a conserved ADP-ribosyl transferase (ART) fold 
and involved in a number of crucial cellular processes that are linked to 
genomic DNA integrity such as DNA repair, genome stability, and cellular 
stress responses [D‟Amours et al, 1999; Ame et al, 2004; Hottiger et al, 
2010]. In the PARP family, only a subset of members is predicted to have the 
ability to produce Poly-ADP-ribose (PARP-1 to PARP-5a and PARP-5b) 
while two are inactive enzymes (PARP-9 and PARP-13) and the remaining 
members are able to produce a mono-ADP-ribose modification [Kleine et al, 
2008]. The 17 members of the PARP family show very different structures 
and cellular functions but are all related by the presence of the PARP 
signature, a conserved PARP catalytic domain [Otto H et al, 2005]. 
The founding and most studied member PARP1 as well as PARP2 
and PARP3 play important roles in the repair of DNA strand breaks and are 
known to be catalytically activated through interaction with DNA damaged 
and catalyze auto-ADP-ribosylation and ADP-ribosylation of other nuclear 
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acceptor proteins [Pascal JM et al, 2015; Martin-Hernandez K et al, 2016; 
Wei H et al, 2016]. PARP1, PARP2 and PARP3 show a characteristic fold 
that is characterized by conserved tryptophan-glycine-arginine (WGR) and 
C-terminal catalytic (CAT) domains and of an N-terminal region (NTR) that 
is really different between the three proteins [Oliver AW et al, 2004]. In fact, 
in contrast to PARP1, the NTRs of PARP-2 and PARP-3 are much shorter 
(78 and 40 residues, respectively), and they do not contain the N-terminal 
zinc finger domains essential for initial DNA binding of PARP1 [Langlier 
MF et al, 2012]. Short NTRs of PARP2 and PARP3 are not strictly required 
for DNA-dependent activation but rather contribute to the overall binding 
affinity and specificity for SSB due to the presence of basic residues in this 
region, as shown for PARP2 [Ame et al, 1999], and contribute to the 
allosteric regulatory mechanism of DNA-dependent catalytic activation via 
local destabilization of CAT through local rearrangements of the WGR 
domain [Dawicki-McKenna JM et al, 2015; Obaji E et al, 2016].  
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Fig. 1.5 Domain architecture of PARP-1, PARP-2 and PARP-3 The WGR and CAT 
domains are conserved, while the N-terminal regions (NTRs) are distinct [John M. Pascal 
Nucleic Acids Research, 2014, Vol. 42, No. 12] 
 
PARP3 has been found to associate with Polycomb group proteins 
involved in transcriptional silencing and with DNA repair networks, 
including base excision repair/single-strand break repair (BER/SSBR) and 
nonhomologous end-joining (NHEJ), suggesting an active role for PARP3 in 
the maintenance of genomic integrity [Rouleau M et al, 2007]. Furthermore, 
PARP3 has been described as a critical player in the stabilization of the 
mitotic spindle and in telomere integrity notably by associating and 
regulating the mitotic components NuMA and Tankyrase 1 suggesting 
PARP3 as a positive regulator of the mitotic network containing Tankyrase 1 
and NuMA with important implications in spindle dynamics and telomere 
integrity during mitosis [Boehler C et al, 2011].  
PARP3 serves TGFβ-dependent epithelial-to-mesenchymal transition 
(EMT), a transdifferentiation programme that is important for organogenesis 
in the developing embryo, tissue injury repair and cancer progression, by 
stimulating a TG2-Snail-E-cadherin axis in a manner involving its response 
to TGFβ-induced ROS [Karicheva O et al, 2016]. The fact that PARP3 is 
upregulated and responds to ROS produced from both exogenous (genotoxic 
agents) and endogenous (TGFβ) sources makes it a major driver of the ROS 
response that is likely to function in various other physiological and 
pathophysiological events. One interesting example is suggested by the 
prominent role of PARP3 in neural crest cell differentiation in the zebrafish 
[Rouleau M et al, 2011], a process in which the generation of ROS by the 
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NADPH oxidase NOX4 was documented to be required for efficient 
differentiation [Lee JE et al, 2014].  
Since point mutations in DNA repair pathways can alter repair 
function and contribute to cancer risk [García-Closas et al. 2006a; Goode et 
al. 2002], in this study we selected some nsSNVs found in cancer tissues and 
annotated in the COSMIC database [Forbes et al, 2010] (F125L, P147T, 
G148D, L233F and F440L) in order to investigate their biophysical and 
biochemical properties respect to its wild-type counterpart. 
 
The data presented in this thesis will provide a comprehensive 
analysis of three-dimensional structure and biophysics of wild-type and 
nsSNVs with the purpose to give a contribution to fill the gap between the 
collection of thermodynamic data and disease-related information on protein 
variants.  
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Chapter 2 
 
Aim of the study 
 
nsSNVs are caused by missense mutations, changes in one DNA 
base pair that result in the substitution of an amino acid in the protein 
encoded by a gene, and contribute to  ̴ 80% of the total number of variants 
annotated as pathogenic. They are the most common type of variation among 
humans and pathogenic nsSNVs, or missense mutations, account for 
approximately half of the allelic variants causative of hereditary disease. 
During the last decade several databases were created collecting data 
associated to protein variations, above all focusing their attention on the 
impact of protein variants at the structural, functional and phenotypic levels. 
Some amino acid substitutions are functionally neutral, however most of 
them may have different effects on protein structure and function and can be 
related to several diseases. It was demonstrated that mutations can frequently 
affect several biophysical characteristics simultaneously and may or may not 
cause diseases [Gong et Blundell, 2010]. Even if the available data on single 
amino acid substitutions are expanding rapidly, the knowledge of the possible 
disease association of nsSNVs and the molecular mechanisms of genetic 
disease is lagging due to the limited integration between experimental data 
and predictions because of the laborious and time consuming nature of 
experimental studies. There is no clear threshold of how large the change of 
the wild-type characteristics should be in order to alter protein function and 
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result in disease. Predictions of damaging effects of mutations are further 
complicated by the observations that enhanced protein activity [Zhang et al, 
2013], higher stability or binding affinity [Witham et al, 2011; Takano et al, 
2012] are not necessarily advantageous for the cell and can be disease 
causing. 
Nowadays several computational methods are available for predicting 
the possible pathogenicity of nsSNVs; they are predominantly based on 
evolutionary information and/or varying structural descriptors of the protein 
in question. These methods aim at automating the annotation process of 
nsSNV effects and therefore would be very useful for the mutation research 
community. In silico study can be useful for obtaining a statistical picture of 
the extent to which these SNVs influence phenotype and for prioritizing 
SNVs for experimental study [Hallali-Assani et al, 2009]. 
Computational analysis has predicted that around 30% of protein variants 
resulting from non synonymous single nucleotide substitutions are less stable 
than the wild-type. Experimental studies have been carried out on very few 
proteins due to the cost and time needed for the entire process  that requires 
mutagenesis, protein expression and purification followed by thermal and 
chemical unfolding [Pasquo A et al, 2012; Lori C et al, 2013; Lori L et al, 
2016; Gao et al, 2015; Petrosino M et al, 2017]. 
In this study I‟m going to present a systematic and qualitative analysis of 
structural and functional properties of protein variants caused by single 
amino acid substitutions leading to non synonymous variants found in cancer 
tissues, including changes in enzyme activity, aggregation propensity, 
structural stability and binding ability. The aim of this study is the 
investigation of plausible correlations, if any, between alteration on protein 
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structure, function or stability caused by single amino acid substitutions and 
cancer.  
During my PhD I focused my attention on three case-reports 
analyzing the expression, the structural characterization and stability and 
binding properties of some variants of three different proteins related to 
several cancer types: 
 Phosphoglycerate kinase 1 (PGK1) is an essential enzyme that 
catalyzes the reversible phosphotransfer reaction from 1,3-
bisphosphoglycerate (1,3-BPG) to MgADP to produce 3-
phosphoglycerate (3-PG) and MgATP, an important ATP-
generating step in glycolysis. Several solid tumors exhibit an 
increased expression of glycolytic enzymes such as PGK1 to 
generate ATP in hypoxic conditions [Hwang et al., 2006; Sun 
et al., 2015] suggesting a plausible role of PGK1 as a cancer 
biomarker.  
 Human Frataxin (hFXN) is a nuclear-encoded protein highly 
conserved implicated in Fe-S cluster biosynthesis and in iron 
and heme metabolism. Iron is an inorganic element which is 
critical for cell proliferation and growth and alterations in 
proteins involved in the regulation of iron levels in cells can 
be dangerous for living organisms and can be related to 
carcinogenesis. 
 Poly (ADP-ribose) polymerase 3 (PARP3) is a member of the 
PARP family, a group of enzymes that synthesize poly (ADP-
ribose) on themselves or other acceptor proteins, that catalyses 
a post-translational modification of proteins involved in 
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biological processes, such as transcriptional regulation, energy 
metabolism and cell death [Hakmé A et al, 2008]. Mutations 
in DNA-repair genes can confer growth and survival 
advantages of cancer cells leading to DNA-repair deficient 
cancers. 
Site-directed mutagenesis has been used to produce recombinant mutant 
proteins in E. coli cells. In this study we characterized the wild-type and the 
variants carrying missense mutations (nsSNVs) and identified in cancer 
tissues in human in order to investigate the impact of these amino acid 
substitutions on protein structure, conformational stability and interactions 
with ligands. We analyzed the effects induced by single amino acid 
substitution on protein structure and function, by means of structural stability, 
binding and activity studies. In particular we selected variants from available 
database such as COSMIC [Forbes et al, 2010] for somatic mutations in 
cancer that stores information about genetic variations on the genomic scale 
and aim to collect mutations in all genes.  
The results obtained during my PhD will be combined with those obtained 
for variants of other proteins studied by our group in the last years: 
Bromodomains (BRDs), Peroxisome Proliferator-Activated Receptor  
(PPAR), Serine/threonine-protein kinase pim-1 (Pim-1) and Protein tyrosine 
phosphatase  (PTP). . This comparative and comprehensive study aims to 
the evaluation of the possible effects that single amino acid substitutions can 
have on protein structure, function or stability. This will be useful to 
understand how missense variants can influence protein properties and which 
can be the correlation, if any, between this type of alterations and cancer.  
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Chapter 3 
 
Methodology 
 
In this study we aimed to investigate the effect or consequences that a 
nsSNV can induce at the level of the protein and for this reason we set an 
adequate experimental procedure. 
 We identified from available databases, such as COSMIC [Forbes et 
al, 2010], OMIM [Hamosh a et al, 2005], Pan-Cancer Atlas 
(https://www.cell.com/pb-
assets/consortium/pancanceratlas/pancani3/index.html) and SNP database, 
nsSNVs of several proteins related to different type of cancers. We chose 
variants of proteins with available PDB in order to map them on the crystal 
structure of the protein. We categorized the nsSNVs into two main groups 
according to their localization on the 3D structure of the protein and 
considering its biological assembly: nsSNVs on surface exposed or buried 
residues, observing that most of the nsSNVs identified are on the protein 
surface and only 31% are buried into the internal part of the protein (Fig. 
3.1).  
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Fig. 3.1  Distribution of nsSNVs based on the structural position of the mutated 
residues. 
 
We designed specific oligonucleotides in order to obtain the selected 
variants and we performed site-directed mutagenesis using Quick Change 
Site-Directed Mutagenesis Kit (Stratagene) to introduce the point mutations 
on wild-type plasmid. The presence of the desired mutations and the absence 
of unwanted mutations were confirmed by sequence analysis. Once obtained, 
we expressed the wild-type and the variants as soluble form in E. coli and 
then we carried out a structural characterization by means of circular 
dichroism and fluorescence spectroscopy. Functional analysis were 
performed and we used Molecular Dynamics simulations to obtain 
information about the dynamic properties of macromolecules and to analyze 
conformational ensembles and X-ray crystallography to solve the crystal 
structure of some of the variants obtaining three dimensional molecular 
features on the possible local structural alterations induced by a point 
mutation. Finally, we performed binding assay using BLI or ITC experiments 
to better understand the binding properties of the selected variants.  
69%
31%
Distribution of the mutated residues based on 
structural position 
Exposed
Buried
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3.1 Protein expression and purification 
 
 The wild-type proteins and their variants were expressed in E. coli 
strain (BL21(DE3) or Rosetta cells) and cultures were grown in LB medium 
containing the optimal antibiotic at 37°C until OD600 arrived to 0.6 and then 
protein expression was induced with 0.5mM or 1mM isopropyl--d-
thiogalactoside (Sigma-Aldrich). After induction, cells were grown at the 
optimal temperature for a period of time well set to obtain a significant 
amount of protein in the soluble fraction; then collected by centrifugation. 
 Every liter of Cell cultures were resuspended in 50 ml of appropriate 
Binding buffer containing 0.5-1 mM tris(2-carboxyethyl)phosphine in the 
presence of protease inhibitors (Complete, Roche) and disrupted by 
sonication. The lysate was cleared by centrifugation and the supernatant was 
purified using affinity chromatography with specific arrangements according 
to the characteristics of each protein of interest. Affinity chromatography is 
one of the most diverse and powerful chromatographic methods for 
purification of a specific molecule or a group of molecules from complex 
mixture,  based on highly specific and reversible interactions between two 
molecules. Affinity chromatographic purification is frequently of great 
importance in the case of recombinant proteins since they are often produced 
in a way that they contain a fused “label” at their N- or C-terminus, resulting 
from genetic engineering. Thanks to that, the recombinant protein can be 
simply “fished out” of the cell extract via affinity chromatography. One of 
the most widely used of such labels fused to protein termini is the oligo-
histidine tag (His-tag), which binds reversibly to metal chelates (Ni chelate 
immobilized on the stationary phase). With the premise that we used 
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plasmids which structures contain a hexahistidine tag cleavable with tobacco 
etch virus protease (Pro-TEV),  the supernatant was loaded on a Ni-NTA 
(Ni2+ - nitriltriacetate) affinity resin (GE Healthcare) pre-equilibrated with 
Binding buffer. The column was washed with Binding buffer to elute weakly 
bound contaminants. The recombinant protein was eluted by passing over the 
column binding buffer solutions containing increasing imidazole 
concentrations (50 mM, 100 mM, 150 mM and 250 mM, respectively). The 
collected eluates were supplemented with a final concentration of 10 mM 
dithiothreitol (DTT) and tested for purity on SDS gel using precasted gel 
system (Invitrogen). The pure fractions were incubated overnight at 4°C with 
tobacco etch virus protease (Pro-TEV), to remove the hexahistidine tag. 
For some of the obtained proteins, such as PGK1 and PARP3, it was 
necessary to adjust the protocol for purification by introducing an upstream 
step: the supernatant was loaded on a DE52 column (GE Healthcare), 
previously equilibrated with Binding buffer and 0.5 mM tris(2-carboxyethyl)-
phosphine, to remove nucleic acids through ion exchange chromatography 
that separates molecules on the basis of differences in their net surface 
charge.  
After digestion, the mixture containing TEV protease, the His-tag and the 
cleaved protein was applied to a 5 ml pre-packed His Trap column (GE 
Healthcare) previously equilibrated in Binding buffer and the flow through 
containing the protein without His-tag was collected and concentrated to 2 ml 
using Millipore concentrators. To achieve a high degree of purity, a further 
purification step was performed according to the characteristics of each 
protein of interest. In the case of PGK1, the collected 2ml were loaded onto a 
Superdex 200 300/10 gel filtration column previously equilibrated with 50 
mM Tris/HCl, 0.25 M NaCl, 10 mM DTT, pH 7.5 at a flow rate of 1.0 
43 
 
ml/min; 2 ml fractions were collected and the pure protein was identified by 
SDS PAGE. In the case of hFXN and PARP3, the collected 2 ml were 
applied to a PD-10 pre-packed column (GE Healthcare). Protein 
concentration was determined spectrophotometrically. 
 
3.2 Spectroscopic measurements 
 
 Intrinsic fluorescence emission measurements were carried out with a 
LS50B spectrofluorimeter (Perkin-Elmer) using a 1.0 cm path length quartz 
cuvette. Fluorescence emission spectra were recorded from 300–450 nm (1 
nm sampling interval), with the excitation wavelength set at 295 nm. Far-UV 
(190–250 nm) CD spectra were recorded either in a 0.1 cm quartz cuvette or 
in a 0.5 cm quartz cuvette; near-UV (240–420 nm) CD spectra were recorded 
at protein concentration ranging from 1.0 to 2.4 mg/ml in a 1.0 cm quartz 
cuvette. The results obtained from the near-Uv CD and far-UV CD spectra 
were expressed as the mean residue ellipticity [], assuming a mean residue 
molecular mass of 110 per amino acid residue. All spectroscopic 
measurements were carried out at 10°C or 20°C.  
 
3.3 Thermal denaturation experiments 
 
 Thermal denaturation experiments were carried out on a JASCO 
circular dichroism (CD) spectropolarimeter. Wild-type and variants (0.20 
mg/ml) were generally heated from 20°C to 80°C in a 0.1 cm quartz cuvette 
with a heating rate of 1.0 and 0.5 degreexmin
-1
 controlled by a Jasco 
programmable Peltier element. The dichroic activity at 209 nm orat 222 nm 
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and the PMTV were continuously monitored in parallel every 0.5°C. All the 
thermal scans were corrected for the solvent contribution at the different 
temperatures. Melting temperature (Tm) values were calculated by taking the 
first derivative of the ellipticity at 208 nm or 222 nm with respect to 
temperature.  
 
3.4 Urea-induced equilibrium unfolding 
  
 For equilibrium transition studies, wild-type and variants were 
incubated at 10°C or at 20°C at increasing concentrations of urea (0–9 M). 
When equilibrium was reached, and intrinsic fluorescence emission and far-
UV CD spectra (0.5 cm quartz cuvette) were recorded in parallel at 10°C or 
at 20°C. To test the reversibility of the unfolding, wild-type and variants were 
unfolded at the same temperature in the optimal urea concentration for 
complete unfolding and, after 10 min, refolding was started by 10-fold 
dilution of the unfolding mixture into solutions of the same buffer used for 
unfolding containing decreasing urea concentrations. After incubation for a 
specific time, required to reach equilibrium from 2h to 24h, intrinsic 
fluorescence emission and far-UV CD spectra were recorded at the chosen 
temperature. 
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3.5 PGK1 enzyme activity and kinetic 
studies 
 
Enzyme activity was determined at 20°C using a standard reaction 
mixture in a final volume of 0.5 ml. At least 10 different concentrations of 
substrates under identical conditions were tested. The reaction was started by 
adding different amounts of purified enzyme ranging from 4 ng to 20 μg. All 
measurements were performed in triplicate in a Lambda 16 computerized 
spectrophotometer (Perkin-Elmer). Kinetic data were analysed according to 
[Chiarelli LR et al, 2012], using GraphPadPrism 5.04.  
The activity assay mixture was also incubated at increasing temperature in a 
thermostated cuvette. Pure enzymes, at 10°C, were added to 0.5 ml of the 
assay mixture equilibrated at the desired temperature to start the reaction. The 
solution was mixed in the thermostated cuvette and the absorbance at 340 nm 
was continuously monitored for 10 min. The changes of enzyme activity as a 
function of temperature was fitted nonlinearly to the Arrhenius equation 
using GraphPadPrism 5.04 to obtain the activation energies (Ea
aǂ) for the 
catalytic reaction 
 
                                              k=Ae
-Ea/RT                         
                            (1) 
 
where k (s
-1
) is the rate constant at temperature T (K), A is a reaction specific 
quantity, R the gas constant (1.987 cal x mol
-1
 x K
-1
) and Ea the activation 
energy of the reaction, as described in [Lori C et al, 2013]. 
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3.6 PGK1 protein crystallization, data 
collection, structures solution 
 The protein samples used for crystallization trials contained protein 
variants at a concentration of 12–18 mg/ml in Tris-HCl 20 mM pH 7.0, in the 
presence of 10 mM ADP, 25mM MgCl2, 50 mM 3-PG and 10 mM DTT. 
Crystals were obtained at 298 K by the hanging-drop vapour diffusion 
method, sealing symmetric drops (1.0+1.0 μL) over 500 μL of reservoir 
solution. A single-wavelength data set was collected at 100 K from each 
crystal and processed with XDS [Kabsch W, 2010] and Aimless [Evans PR et 
al, 2013]. The structures were determined by molecular replacement with the 
program MOLREP (CCP4 suite) [Vagin A et al, 1997] using the PDB entries 
2WZB and 2ZGV as search models for closed and partially closed 
conformations respectively. Refinement has been performed using the 
maximum-likelihood method with the program REFMAC [Murshudov GN et 
al, 1997] and model building has been done by using Coot [Emsley P et al, 
2004].  
 
3.7 hFXN stopped-flow measurements 
 
 Kinetic (un)folding experiments were carried out on a single-mixing 
SX-18 stopped-flow instrument (Applied Photophysics, Leatherhead, UK) 
the reaction being followed by tryptophan emission. The excitation 
wavelength was 280 nm and emission was collected using a 320 nm cut-off 
glass filter. 
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Final protein concentration was typically 2M. The experiments were 
performed at 37°C with 8 M urea.  
 
3.8 Data analysis 
 
3.8.1 Quantitative analysis of equilibrium 
transition 
 
The changes in intrinsic fluorescence emission spectra at increasing urea 
concentrations were quantified as the intensity-averaged emission 
wavelength, , [Royer CA et al, 1993] calculated according to 
 
=  (Iii)/(Ii)                                                                     (2) 
 
where i and Ii are the emission wavelength and its corresponding 
fluorescence intensity at that wavelength, respectively. This quantity is an 
integral measurement, negligibly influenced by the noise, which reflects 
changes in the shape and position of the emission spectrum. Urea-induced 
equilibrium unfolding transitions monitored by far-UV CD ellipticities 
changes was analysed by fitting baseline and transition region data to a two-
state linear extrapolation model [Santoro MM et al, 1998] according to 
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Gunfolding = G
H
2
O
 + m [urea] = −RT ln Kunfolding                                                        (3) 
 
where Gunfolding is the free energy change for unfolding for a given denaturant 
concentration, GH2
O
 the free energy change for unfolding in the absence of 
denaturant and m a slope term which quantifies the change in Gunfolding per 
unit concentration of denaturant, R the gas constant, T the temperature and 
Kunfolding the equilibrium constant for unfolding. The model expresses the 
signal as a function of denaturant concentration:      
iy
   
 
2
2
N N U U[ ] [ ] *exp [ ] /
[ ]
1 exp
H O
i i i
H O
i
y s X y s X G m X RT
G m X
RT
     
 
  
  
  
                   (4) 
 
where yi is the observed signal, yU and yN are the baseline intercepts for 
unfolded and native protein, sU and sN are the baseline slopes for the unfolded 
and native protein, [X]i the denaturant concentration after the addition, G
H
2
O
 
the extrapolated free energy of unfolding in the absence of denaturant, m the 
slope of a Gunfolding versus [X] plot. Data were globally fitted with the m 
values shared between the data sets; all other parameters were not 
constrained. The denaturant concentration at the midpoint of the transition, 
[Urea]0.5, according to equation 2, is calculated as: 
 
                                                            [urea]0.5= G
H
2
O
 /m                                                                          (5) 
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All unfolding transition data were fitted by using Graphpad Prism 5.04. 
Far-UV CD spectra recorded as a function of urea concentration were 
analyzed by a singular value decomposition algorithm (SVD) using the 
software MATLAB (Math-Works, South Natick, MA) to remove the high 
frequency noise and the low frequency random errors and to determine the 
number of independent components in any given set of spectra. CD spectra in 
the 213–250 nm or in the 250-320 nm region were placed in a rectangular 
matrix A of n columns, one column for each spectrum collected at each time. 
The A matrix is decomposed by SVD into the product of three matrices: A = 
U*S*V
T
, where U and V are orthogonal matrices and S is a diagonal matrix. 
The U matrix columns contain the basis spectra and the V matrix columns 
contain the urea dependence of each basis spectrum. Both U and V columns 
are arranged in terms of decreasing order of the relative weight of 
information, as indicated by the magnitude of the singular values in S. The 
diagonal S matrix contains the singular values that quantify the relative 
importance of each vector in U and V. The signal-to-noise ratio is very high 
in the earliest columns of U and V while the random noise is mainly 
accumulated in the latest U and V columns. The wavelength averaged 
spectral changes induced by increasing denaturant concentrations are 
represented by the columns of matrix V; hence, the plot of the columns of V 
versus the denaturant concentrations provides information about the observed 
transition. 
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3.9 Cell culture 
 
Human gliomablastoma cell line LN229 were maintained in 
Minimum Essential Media (MEM) with 10% fetal bovine serum (FBS) and 
1% gentamycin (Invitrogen) in a humidified incubator with 37°C and 5% 
CO2. MDA MB231 PARP3
-/-
 cells and MDA MB436 PARP3
-/-
 breast cancer 
cells were maintained in RPMI 1640 medium with 10% fetal bovine serum 
(FBS) and 1% gentamycin (Invitrogen) in a humidified incubator with 37°C 
and 5% CO2.  
 
3.10 Western blot analysis 
 
For PARP3 expression analysis in LN229 cell lines, cells were 
collected and pellet was resuspended in hypotonic buffer (10mM Tris pH 7.3, 
10mM KCl, 1.5mM MgCl2, 10mM β-mercaptoethanol, 0.2mM PMSF). After 
centrifugation at 4000 rpm at 4°C for 5 min, the supernatant was removed 
and the pellet was resuspended using extraction buffer (15mM Tris pH 7.3, 
0.4 mM NaCl, 1mM EDTA, 1mM MgCl2, 10% glycerol, 10mM β-
mercaptoethanol, 0.2mM PMSF). After incubation for 30 min. in ice, the 
samples were centrifuged at maximum speed at 4°C for 30 min. The cleared 
suspension was quantified by Bradford protein assay. Equivalent amounts of 
proteins were next analysed by 10% SDS-PAGE and Western blot analysis 
were performer using the appropriate antibodies. Bands were visualized using 
ECL-PLUS detection system (Amersham Biosciences) and the images were 
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captured using the Image Quant LAS 4000 imaging system (GE Healthcare 
Life Science). 
 
3.11 Dose response 
 
In order to induce DNA damage and thus to observe the involvment 
of PARP3 in DNA repair, we treated our cell lines with chemotherapeutic 
drugs, such as Temozolomide (TMZ) and Phleomycin (Phleo). We evaluate 
the IC50 in order to decide the concentration to use for the kinetic assay. 
 
3.12 Clonogenic assay 
 
Clonogenic assay, or colony formation assay, is an in vitro cell 
survival assay based on the ability of a single cell to grow into a colony. We 
analyzed the colony formation propensity of each cell line. After 10 days we 
fixed and stained the colonies: 
1. Gently remove the media from each of the plates by aspiration. 
2. Wash each plate with 5 ml 0.9% saline. 
3. Fix the colonies with 5 ml 10% neutral buffered formalin solution for 15-
30 minutes. 
4. Stain with 5 ml 0.01% (w/v) crystal violet in dH2O for 30-60 minutes. 
5. Wash excess crystal violet with dH2O and allow dishes to dry. 
Finally digital images of the colonies were obtained using a camera or 
scanning device and colonies were counted using imaging analysis software. 
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3.13 PARP3 transfection in human breast 
cancer cell lines  
 
MDA MB231 PARP3
-/-
 cells and MDA MB436 PARP3
-/-
 breast 
cancer cells were transfected with an empty vector (pEGFP), with the PARP3 
wild-type (pEGFPhP3) and with two variants of the PARP3 WGR domain 
(pEGFPhP3-P147T, pEGFPhP3-G148D) and with one variant of the PARP3 
CAT domain (pEGFPhP3-F440L).  
300000 cells were plated in a P60 plate and transfection was induced after 
24h, when a confluence of 50-80% was reached. In an eppendorf tube the 
necessary volumes of OptiMEM medium and Fugene 6 were mixed and then 
the plasmids with DNA (5µg) were added. After incubation for 15 min at 
room temperature, the mixtures were added using a pipette while trying to 
distribute the drops on the entire surface of the P60 and at the end, and the 
plates were moved by circular motions for a better distribution of the 
solution. The transfected cells were mainteined at 37°C in a humidified 
incubator with 37°C and 5% CO2. The cell culture medium was changed 48 
hours after transfection and the stable transfectants were selected with 
neomycin at 500 μg/ml and 250 μg/ml in MDA MB231 cells and in MDA 
MB436 cells respectively. Breast cancer cell lines were maintained in RPMI 
1640 medium with 10% fetal bovine serum (FBS) and 1% gentamycin 
(Invitrogen) in a humidified incubator with 37°C and 5% CO2.  
 
 
53 
 
Chapter 4 
 
Results  
 
Point mutations can induce multiple effects on a given protein: 
nsSNVs can be beneficial, adding new functionality and increasing the 
fitness of the cell or deleterious, damaging the protein, causing 
destabilization of the protein structure or reducing its functional activity 
because of the disruption of a site that is directly involved in the function of 
the protein and thereby contributing to disease phenotypes [Studer et al, 
2013]. Change in amino acids with similar size and physico-chemical 
properties (e.g. substitution from leucine to valine) has a mild effect. 
Similarly, if the point mutation disrupts secondary structure elements (e.g. 
substitution to proline in alpha helix region) such mutation usually may affect 
protein structure, function and stability. Interestingly, several nsSNVs have 
been found in different types of cancer leading researchers to some questions: 
“how missense variants can influence protein properties?  
In order to give an overview of the possible effect or consequences 
that a single amino acid substitution can have on a given protein, we analyzed 
45 nsSNVs of different proteins found in cancer tissues. We chose proteins 
with available crystal structures in order to locate the position of the amino 
acid change present in nsSNV within them. In the last years we published 
some works regarding this topic in which we analyzed the biochemical 
properties of several nsSNVs of some proteins that seems to be widely 
mutated in different cancer types: the Bromodomains (BRDs) [Lori L et al, 
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2016], the Peroxisome Proliferator-Activated Receptor  (PPAR) [Petrosino 
M et al, 2017], the Serine/threonine-protein kinase pim-1 (Pim-1) [Lori C et 
al, 2013] and the Protein tyrosine phosphatase  (PTP) [Pasquo A et al, 
2012]. I will combine the results obtained for these proteins with that 
obtained for the variants of PGK1, hFXN and PARP3, that I analyzed during 
my PhD, in order to set a comparative work with the aim to fill the gap 
between the collection of biochemical data and cancer-related information on 
protein variants. 
For each protein we chose variants with an high pathogenic score 
(Table 4.1), a significant value generally used to give reason of the 
pathogenic rate. It is derived from the new FATHMM-MKL 
(http://fathmm.biocompute.org.uk/) algorithm that predicts the functional, 
molecular and phenotypic consequences of protein missense variants using 
hidden Markov models. The functional scores for individual mutations from 
FATHMM-MKL are in the form of a single p-value, ranging from 0 to 1. 
Scores above 0.5 are deleterious, but in order to highlight the most significant 
data in COSMIC, only scores ≥ 0.7 are classified as 'Pathogenic'. Mutations 
are classed as 'Neutral' if the score is ≤ 0.5. [Shihab Hashem A et al, 2015]. 
 
Protein Variant Pathogenic score Primary Tissue 
BRD4(1) A89V 0.95 Large intestine 
BRD2(1) R100L 0.93 Lung 
BRD2(1) E140K 0.99 Lung 
BRD2(1) Y153H 0.99 Endometrium 
BRD2(1) D160N 0.99 Ovary 
BRD2(1) D160Y 0.99 Ovary 
BRD2(2) G355D 0.97 Large intestine 
BRD3(2) H395R 0.96 Lung 
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BRD2(2) R419W 0.89 Skin 
BRD2(2) P430S 0.96 Large intestine 
BRD2(2) Q443H 0.99 Large intestine 
BRD4(2) A420D 0.99 Lung 
hFXN D104G 0.96 Liver 
hFXN A107V 0.85 Large intestine 
hFXN F109L 0.72 Endometrium 
hFXN Y123S 0.96 Upper aerodigestive tract 
hFXN S161I 0.99 Endometrium 
hFXN W173C 0.99 Oesophagus 
hFXN S181F 0.95 Skin 
hFXN S202F 0.50 Skin 
PARP3 F125L 0.97 Large intestine 
PARP3 P147T 0.72 Breast 
PARP3 G148D 0.97 Liver 
PARP3 L233F 0.93 Oesophagus 
PARP3 F440L 0.97 Lung 
PGK1 R39M 0.99 Lung 
PGK1 R66W 0.94 Liver 
PGK1 G167D 0.98 Endometrium 
PGK1 M190I 0.99 Breast 
PGK1 A200V 0.98 Breast 
PGK1 V217F 0.98 Breast 
PGK1 F242S 0.91 Breast 
PIM1 E124K 0.99 Urinary tract 
PIM1 V126A 0.91 Urinary tract 
PIM1 E135K 0.97 Haematopoietic and lymphoid 
PIM1 E142D 0.88 Haematopoietic and lymphoid 
PPAR Q286P 0.90 Colon 
PPAR R288H 0.95 Colon 
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PPAR E324K 0.99 Endometrium; Skin 
PPAR R357C 0.88 Lung 
PPAR E460K 0.73 Lung 
PTP D927G 0.91 Colon 
PTP Q987K 0.91 Colon 
PTP A1118P 0.89 Colon 
PTP N1128I 0.91 Rectum 
 
Table 4.1 Forty-five analyzed nsSNVs. List of the analyzed nsSNVs with their pathogenic 
score and the primary tissue in which they have been found. 
 
By determining the location of the amino acid change on the protein 
structure, we manually categorized the nsSNVs into two groups: 69% of the 
nsSNVs involved solvent exposed residues and 31% were buried into the 
protein (Fig. 3.1).  
 
4.1 Experimental analysis of PGK1 nsSNVs  
 
In order to understand the structural and functional consequences of 
non synonymous changes, in this study we selected seven PGK1 variants 
(R38M, R65W, G166D, M189I, A199V, V216F and F241S) found in cancer 
tissues and annotated in the COSMIC database and we report the effect of 
these variants analyzing the structure, the conformational stability, the 
protein folding and the kinetic behaviour compared with its wild-type 
counterpart. The selected variants involved residues located in the 3-PG 
binding domain, in the nucleotide binding domain and in the hinge region 
that connects the two domains (Fig. 4.1).  
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Fig. 4.1 Amino acid sequence and structure of PGK1. N-terminal domain (violet), C-
terminal domain (green), hinge region (blue) (PDB: 2XE7, open conformation). (A) 
Secondary structural elements are shown at the top of the amino acid sequence. Mutated 
residues are depicted in bold red. The dots under the sequence represent the residues 
involved in 3-PG or 1,3-BPG binding (pink dot) and in ATP or ADP binding (green dot). (B) 
Location of the mutations on PGK1 structure (open conformation). Mutated residues are 
depicted in scaled ball and stick and 3-PG and ADP in stick. 
https://doi.org/10.1371/journal.pone.0199191.g001 
 
4.1.1 Spectroscopic characterization of PGK1 
wild-type and variants 
 
Using CD and fluorescence spectroscopy we performed a detailed analysis 
of the conformation in solution of all PGK1 variants. The near-UV CD 
spectrum of PGK1 wild-type represent the spectral contributions of all 
aromatic residues and is characterized by a strong positive peak centred at 
around 292 nm flanked by a shoulder at 286 nm and by negative 
contributions in the region between 255 and 270 nm, with two peaks centered 
at 262 and 268 nm (Fig. 4.2A). We observed only small conformational 
58 
 
changes: R38M, G166D, A199V and V216F display near-UV CD spectra 
closely similar to that of the wild-type, except for a slight difference at 277 
nm observed for G166D, however significant differences are observed in the 
near UV CD spectra of M189I, F241S and R65W. In the case of M189I and 
F241S, the contributions at 262 nm and 268 nm are positive; in addition, the 
spectrum of M189I loses fine structure features in the region between 270 
and 280 nm. The variant R65W shows a near-UV CD spectrum that 
significantly differs from that of the wild-type in intensity, consistent with the 
substitution of an arginine residue with a tryptophan. The fluorescence 
spectra of wild-type and variants are centred at the same maximum emission 
wavelength  at around 350 nm, characteristic of tryptophan contribution, with 
differences in the relative fluorescence emission intensity which is 
significantly decreased for A199V and increased for R65W, M189I and 
V216F (Fig. 4.2B).  
The far-UV CD spectra of PGK1 wild-type and variants show the typical 
local minimum contributions of alpha helical proteins at around 208 nm and 
at 222 nm (Fig. 4.8C). The molar ellipticity  ratio at 222 and at 208 nm 
(222/208) is indicative of interhelical contacts present in helix bundle 
and coiled coil structures and it is generally used to distinguish between 
coiled coil helices ( >1.0) and non-interacting helices (0.8-0.9) [Shermann 
MA et al, 1992; Choy N et al, 2003]. The  222/208 is 1.2 for the wild-
type, it is decreased to 1.1 only for the variants R38M and M189I and it is 
increased to 1.3 for V216F. Notably, in the case of M189I the far-UV 
dichroic activity is decreased with respect to that of the wild-type (Fig. 4.2C). 
These differences in secondary structure may suggest differences in 
interhelical interactions and dynamic fluctuation in solution for some of 
PGK1 variants. 
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Fig. 4.2 Spectroscopic characterization of PGK1 wild-type and variants. (A) Near-UV 
CD spectra were recorded in a 1.0-cm quartz cuvette at 1.5-1.7 mg/ml protein concentration 
in 20 mM Tris-HCl pH 8.0 containing 2.0 mM DTT, 1 mM EDTA and 200 mM NaCl. (B) 
Intrinsic fluorescence emission were recorded at 110 g/ml for R65W and 130 μg/ml for 
wild-type and the other variants spectra (0.08 AU280nm, 295 nm excitation wavelength), in 
20 mM Tris-HCl, pH 8.0 containing 0.2 M NaCl and 0.2 mM DTT. (C) Far-UV CD spectra 
were recorded in a 0.1-cm quartz cuvette at 130-170 g/ml in 20 mM Tris-HCl, pH 7.5 
containing 0.2 M NaCl and 0.2 mM DTT. All spectra were recorded at 20°C. 
 
4.1.2 Kinetic analysis  
 
 The effect of non synonymous single nucleotide substitutions on the 
kinetic properties of PGK1 enzyme was investigated performing the reverse 
reaction at 20°C at a fixed concentration of free Mg
2+
 and using 3-PG as 
variable substrate. All the variants displayed a reduced catalytic efficiency 
analyzed using 3PG as variable substrate over the concentration range 0.05-
15.0 mM, with the exception of  F241S that displays a two fold increase of 
activity (Table 4.2). The decrease of the enzyme activity was particularly 
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evident for the variant R38M, that showed a decrease of eight order of 
magnitude, due to a dramatic decrease of the turnover number and to an 
increase of KM. R38, located in the 3-PG binding site, is critical for the 
positioning of the substrate in the catalytic site and for the stabilization of the 
transition state because it interacts electrostatically with hydrogen bound with 
the carboxyl group of 3-PG. 
The temperature dependence of the kinase activity of PGK1 wild-type and its 
variants using a low concentration of 3- PG substrate (0.02 mM, well below 
the KM value) was analysed over the temperature range of 10–42°C (Fig. 4.3) 
to study the enzymatic release of substrate and product that may be related to 
its flexibility. The optimal temperatures for catalysis in these conditions were 
estimated to be 37°C for the wild-type and most of the variants, around 35°C 
for F241S, and around 40°C for R38M and V216F (Table 4.3 and Fig. 4.3). 
As shown in Table 4.3, the lowest value of the activation energy (Ea
‡
) is that 
of the F241S variant (6.39 kcal∙mol−1) which is also the variant displaying a 
kcat higher than that of the wild-type enzyme (213.0 vs 89.8 s
-1
). As 
mentioned before, the activation energies have been measured at a 3-PG 
concentration of 0.02 mM, well below the KM value. At this substrate 
concentration, the enzyme is not saturated, the complex enzyme-3-PG-ATP 
may dissociate to form again the enzyme-ATP complex and free 3-PG or 
may catalyse the formation of the two products ADP and 1,3-BPG. The 
activation energy measured in these conditions reflects the enzymatic release 
of both the substrate and the product and it may be related to the enzyme 
flexibility. 
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Fig. 4.3 Effect of temperature on kinase activity of PGK1 wild-type and variants. (A) 
Temperature dependence of kinase activity of PGK1 wild-type and variants. (B) Non-linear 
fit of the temperature dependence of PGK1 activity to the Arrhenius equation Eq (1). Assays 
were performed under the conditions described in Materials and Methods, using 0.18-12.0 
nM enzyme. https://doi.org/10.1371/journal.pone.0199191.g002 
 
Table 4.2 Kinetic parameters of PGK1 wild-type and variants. PGK1 activity was 
determined at 20°C, with 3-PG and 5 mM MgATP (fixed substrate concentration), as 
described in Materials and Methods. Kinetic parameters for PGK1 activity were determined 
at 20°C by using at least at 10 different concentrations of 3-PG. Data are reported as the 
mean ± SE of the fit. https://doi.org/10.1371/journal.pone.0199191.t001 
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Table 4.3 Effect of temperature on kinase activity of PGK1 wild-type and variants Ea
aǂ 
was determined by the Arrhenius equation Eq (1) in the temperature range between 10 °C 
and the optimal temperature of each protein. 
https://doi.org/10.1371/journal.pone.0199191.t002 
 
4.1.3 Thermal and thermodynamic analysis 
  
The thermal stability of PGK1 wild-type and variants was investigated in 
the temperature range between 20°C and 80°C by continuously monitoring 
the ellipticity changes at 222 nm, where the main amplitude was observed 
(Fig. 4.4A,B). The thermal denaturation process is irreversible and occur in 
an apparent cooperative transition. The parameter chosen to compare the 
transition curves of the proteins is the melting temperature (Tm) defined as 
the midpoint of the denaturation process and calculated by plotting the first 
derivative of the molar ellipticity values as a function of temperature (Fig. 
4.4A, insert). Tm values range from 49.0°C to 53.5°C (Table 4.4). The variant 
R65W shows the same Tm value of the wild-type, a modest increase in Tm 
values is observed for the variants G166D and A199V; all the other variants 
show Tm values lower than that of the wild-type, with F241S showing a Tm 
value three degrees below that of the wild-type (Table 4.4). Notably, the 
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differences in the amplitude observed for the thermal transitions of most of 
the variants (4.4B) may be referred to the difference in the dichroic activity at 
222 nm of their corresponding native states, as also indicated in far-UV CD 
spectra reported in Fig. 4.2C. 
The thermodynamic unfolding parameters of PGK1 wild-type and 
variants have also been detected, since they reversibly unfold in urea at 20°C. 
The effect of increasing urea concentrations (0–8 M) on the protein structure 
was analyzed by far-UV CD and fluorescence spectroscopy (Fig. 4.4C,D). 
The fluorescence changes at increasing urea concentration were measured by 
calculating the intensity averaged emission wavelengthλ , an integral 
measurement that depends both on the position and the shape of the 
spectrum. The same samples used to monitor the fluorescence changes during 
the unfolding transitions were used to monitor the far-UV CD ellipticty 
changes, to allow a direct comparison of the data. The urea-induced changes 
in 222 nm ellipticity and in the emission fluorescence show a sigmoidal 
dependence on urea concentration and follow an apparent two-state transition 
without any detectable intermediate (Fig. 4.4C,D). The unfolding process is 
fully reversible upon dilution of the denaturant either for the wild-type and 
variants. The thermodynamic parameters G
H
2
O
, the free energy change for 
unfolding in the absence of denaturant, and m, a parameter that refers to the 
amount of protein surface area exposed to the solvent during unfolding, have 
been obtained using a two-state model (Table 4.4). G
H
2
O
 values of  PGK1 
variants are similar to those of the wild-type with the exception of G166D, 
M189I and F241S that show a significant decrease in the thermodynamic 
parameters (Table 4.4), mainly due to a decrease in m values which suggests 
either a destabilization of the native state or the presence of unfolding 
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intermediates not detectable at the equilibrium. The occurrence of 
undetectable unfolding intermediates may be the case of R38M and G166D 
as suggested by the non coincidence of the [Urea]0.5 values obtained by far-
UV CD and fluorescence changes, mainly due to the differences in m value 
(Table 4.4). 
 
  
Tm 
(°C) 
G
H
2
O
 (kcal∙mol−1) m (kcal∙mol−1∙M-1) [Urea]
0.5
 (M) 
  
 
CD ([]222) 
Fluorescence 
(λ) 
CD ([]222) 
Fluorescence 
(λ) 
CD 
([]222) 
Fluorescence 
(λ) 
Wild-type 52.5 8.29 ± 0.57 8.06 ± 0.46 3.54 ± 0.25 3.10 ± 0.17 2.34 2.60 
R38M 51.5 6.91 ± 0.73 5.54 ± 0.37 3.54 ± 0.37 1.87 ± 0.12 1.95 2.96 
R65W 52.5 7.04 ± 0.32 7.20 ± 0.66 3.07 ± 0.14 2.63 ± 0.24 2.29 2.73 
G166D 53.0 4.19 ± 0.31 4.94 ± 0.29 2.33 ± 0.16 1.51 ± 0.09 1.75 3.27 
M189I 50.5 4.87 ± 0.31 5.01 ± 0.48 2.36 ± 0.15 1.82 ± 0.17 2.06 2.75 
A199V 53.5 7.14 ± 0.57 6.82 ± 0.72 3.41 ± 0.14 2.71 ± 0.22 2.23 2.63 
V216F 52.0 6.45 ± 0.34 5.76 ± 0.54 2.99 ± 0.16 2.14 ± 0.20 2.16 2.69 
F241S 49.0 3.02 ± 0.17 3.80 ± 0.26 2.06 ± 0.10 1.67 ± 0.11 1.47 2.27 
 
Table 4.4 Melting temperatures and thermodynamic parameters for urea-induced 
unfolding equilibrium of PGK1 wild-type and mutants measured by far-UV CD and 
fluorescence spectroscopy. The temperature-induced changes were followed by monitoring 
the ellipticity at 222 nm. The Tm values were calculated by taking the first derivative of the 
ellipticity at 222 nm with respect to temperature. Urea-induced unfolding equilibrium data 
were measured at 20°C by monitoring ellipticity at 222 nm [Θ222 ] and fluorescence intensity 
averaged emission wavelength λ. G
H
2
O
 and m values were obtained from Eq 3; [Urea]0.5 
was calculated from Eq 5. Data are reported as the mean ± SE of the fit. 
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Fig. 4.4 Thermal unfolding and urea-induced equilibrium unfolding of PGK1 wild-type 
and variants. PGK1 variants and wild-type (130 - 170 g/ml) were heated from 20°C to 
80°C in 20 mM Tris-HCl, pH 8.0 containing 0.2 M NaCl  and 0.2 mM DTT . The molar 
ellipticity at 222 nm ([Θ222]) was monitored continuously every 0.5 °C. (A) Normalized 
[Θ222]; the inset shows the first derivative of the same data as in (A). (B) [Θ222] before 
normalization. of PGK1 wild-type and variants. (C) Normalized intensity-averaged emission 
wavelength λ). (D) Normalized molar ellipticity at 222 nm ([Θ222]) reported after of the 
high-frequency noise and the low-frequency random error by SVD. The continuous lines 
represent the nonlinear fitting of the normalizedλ and [Θ222] data to Eq 4. The reversibility 
points (empty circles) are shown, for clarity, only for the wild-type and were not included in 
the nonlinear regression analysis. All spectra were recorded at 20 °C. 
 
C 
D 
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4.1.4 Structural analysis  
 
We investigated the structure of PGK1 variants in the presence of Mg-
ADP and 3-PG through X-ray crystallography in order to reveal possible 
local and global variations with respect to the wild-type protein. We succeed 
in solving the X-ray crystal structures of the variants with mutation in the N-
terminal region as R38M and G166D, in the C-terminal region as V216F and 
in the hinge region as M189I. We solved the structures of all these mutants in 
the partially closed conformation, and we succeed to solve the structure of 
M189I also in the totally closed conformation. The overall structure is 
conserved in all the mutants compared to the wild-type (Table 4.5). The 
details of local variation are discussed case-by-case.  
Mutant Domain Role/position of 
mutated residue 
Conformation Ligands  RMSD# ( Å2) 
 
R38M 3-PG-
binding 
Binding of 3PG, 
charge balancing 
in the transition 
state 
Partially 
closed 
Mg-ADP vs 2ZGV*: 0.23  
vs 2XE7*: 0.96 
G166D 3-PG-
binding 
Close to 3PG 
COO- 
Partially 
closed 
Mg-ADP vs 2ZGV*: 0.62 
vs 2XE7*: 1.17  
V216F ADP-
binding 
Part of the 
catalytic loop 
211-219 that 
favors closed 
conformation 
Partially 
closed 
Mg-ADP, 
3-PG 
vs 2ZGV*: 0.60 
vs 2XE7*: 1.22 
M189I Hinge N-terminal 
portion of the 
hinge 
Partially 
closed 
Mg-ADP, 
3-PG 
vs 2ZGV*: 0.60 
vs 2XE7*: 1.18 
Closed Mg-ADP, 
3-PG 
vs 2WZB*: 0.25 
 
67 
 
Table 4.5 Superimposition between the PGK1 wild type and the crystallized variants. 
RMSD#: root mean square deviation obtained from the superimposition of each variant with 
respect to wild-type PGK1. *2ZGV: wild-type binding Mg-ADP; 2XE7: wild-type binding 
Mg-ADP and 3-PG; 2WZB: wild-type binding Mg-ADP, 3-PG and MgF3
- 
 
The residue R38 is placed in the N-terminal 3-PG binding domain and is a 
residue important for the substrate binding and its correct positioning to react 
with ADP (Fig 4.5). Moreover, together with residues K215 and K219, R38 
is critical for charge balancing of the transition state, directly interacting with 
the transferring phosphate group in the closed conformation of PGK1. 
The crystal structure of R38M does not contain 3-PG (Fig. 4.5A), in line 
with the role of R38. This finding could account even for the reluctance to 
crystallize in the closed form since the binding of both substrates is required 
for the stabilization of this conformation. Taken together these observations 
justify the dramatic effect of R38M mutation on kinetic parameters (see 
Table 4.2). Indeed, upon R38M mutation the KM increases from 0.40 to 3.15 
mM and the turnover number strongly decreases from 89.8 to 7.2x10
-6
 s
-1
. 
Apart for the mutation, the position of the residues in the 3-PG binding 
pocket is very similar to that of the wild-type without 3-PG (PDB code: 
2ZGV, Fig. 4.5B). The only differences between the two structures concern 
the α-helix 374-382, visible in the R38M variant but not in the wild-type 
2ZGV structure, and the position of the β-phosphate group, which in R38M 
points towards the helix (Fig. 4.5A). However, both the helix and the 
phosphate present some variability upon different PGK1 structures indicating 
that it could be dependent on crystallization conditions. 
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Fig. 4.5 Detail of the 3-PG binding site in the variant R38M in comparison with PGK1 
wild-type. Overlap of R38M variant (green) and PGK1 wild-type crystallized (A) in the 
absence of 3-PG (PDB 2ZGV) (light grey) or (B) in the presence of 3-PG (PDB: 2XE7) 
(grey). https://doi.org/10.1371/journal.pone.0199191.g003 
 
G166 is one of the residues lining the 3-PG binding site and its 
substitution for the bulky and negatively charged aspartate modifies the shape 
and the charge of the substrate binding pocket. The structure of G166D (Fig 
4.6) reveals that the aspartate engages R38 in a salt bridge (OD-(D166)-
NH1(Arg38)=3.3Å) altering its capability of interaction. These modifications 
of the pocket prevent the binding of 3-PG, that is not present in the structure, 
and the stabilization of the transition state through R38, thus affecting both 
kcat (5.9 s-1) with a 15-fold decrease, and KM (1.54 mM) increased 4- fold. 
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Fig. 4.6 Detail of the 3-PG binding site in the variant G166D in comparison with PGK1 
wild-type. Overlap of G166D variant (cyan) and PGK1 wild-type crystallized (A) in the 
absence of 3-PG (PDB 2ZGV) (light grey) or (B) in the presence of 3-PG (PDB: 2XE7) 
(grey). https://doi.org/10.1371/journal.pone.0199191.g004  
 
V216 belongs to the loop 214-219, close to the ADP-binding site. The 
rearrangement of this loop has been suggested to be important for the 
preparation of closed conformation by binding of ligands [Zerrad L et al, 
2011]. Indeed, upon ADP-binding to wild-type the loop assumes two 
conformations, promoting the reorientation of K215 and D218, now ready to 
interact with -phosphate of 3-PG and D65, in the closed conformation. In the 
variant V216F, the loop adopts the same conformation as in apo-PGK1. As 
shown in Fig. 4.7B the substitution of the valine with a phenylalanine keeps 
the loop in this conformation since the aromatic residue tends to stay buried. 
The lower mobility of the loop hampers the transition from the open to the 
closed conformation affecting the enzyme catalytic activity  (the kcat of the 
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mutant is 1.9 s
-1
, 45-fold lower than that of the wild-type). Conversely, no 
variation is found in ADP-binding. In fact, as shown in Fig. 4.7, the residues 
directly involved in the binding (E343, G312, A214) and the Mg(II) ion 
bound trough the β and -phosphate and D374 conserve the same positions as 
in the wild-type structure.  
 
 
 
 
 
 
 
 
 
Fig. 4.7 ADP binding site in the variant V216F in comparison with PGK1 wild-type. (A) 
Detail of the binding of ADP to V216F variant (orange). (B) Superimpostition with wild-
type PGK1 crystallized with ADP and 3-PG (PDB: 2XE7) (grey), highlighting how the 
mutation V216F impairs the movement of the loop 212-218. The residue V/F216 and ADP 
are shown as sticks. https://doi.org/10.1371/journal.pone.0199191.g005 
 
Residue 189 is part of helix 189-201, the hinge connecting the N-terminal 
3-PG binding domain and the C-terminal ADP binding domain. The structure 
of M189I has been solved both in open and closed conformation. As for the 
other variants, M189I partially open structure is coincident to that of the 
wild-type  but in this case both ADP and 3-PG are clearly visible. It should 
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be noticed that in the M189I the hydroxyl carboxylate moiety of the 3-PG is 
90°-rotated with respect to the position adopted in the wild-type structure. 
This could be due to the presence, in the active site, of a phosphate ion which 
may induce a change in the mode of 3-PG binding (Fig. 4.8A). Since M189I 
mutation causes neither overall nor local conformational change, the KM of 
the mutant is very similar to that of the wild-type protein (0.58  mM vs 0.40 
mM) and the kcat is only three times lower than that of wild-type protein (30.5 
vs 89.8 s
-1
). The structure in closed conformation was obtained in the same 
condition of the wild-type protein (PDB 2WZB). As shown in Fig. 4.8B, the 
structure appear to be identical to the wild-type ones; also the position of the 
two ligands, ADP and 3-PG, is conserved. Interestingly, in the M189I 
structure in closed conformation MgF3
-
 is not present and therefore the 
transition complex does not form in the M189I variant. Nevertheless, all the 
residues stabilizing the transition state conserve the same positions.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.8 M189I variant in comparison with PGK1 wild-type. (A) Detail of the binding of 
3-PG to M189I variant in the partially-closed conformation (magenta) (B) Superimpostition 
of M189I variant in the closed conformation (pink) with wild-type PGK1 crystallized with 
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ADP, 3-PG and MgF3
- (PDB: 2WBZ) (deep teal). MgF3
- is shown as green and cyan spheres. 
https://doi.org/10.1371/journal.pone.0199191.g006 
 
4.2 Experimental analysis of hFXN nsSNVs 
 
The eight human Frataxin (hFXN) variants, associated to human 
carcinoma reported in this study were mined from the COSMIC database  
(http://cancer.sanger.ac.uk/cosmic) [Forbes SA et al, 2017]. The variant 
D104G is reported to be present in liver carcinoma, A107V, Y123S and 
W173C are reported in carcinoma from diverse locations of the digestive 
tract, F109L and S161I from endometrium carcinoma and S181F and S202F 
from skin malignant melanoma and carcinoma, respectively. In Figure 4.9 is 
reported the location of the selected mutants mapped onto the hFXN 
structure. It is noteworthy that all the residues are solvent exposed. Residues 
D104, A107 and F109 are located in the 1 helix, which belongs to the 
hFXN acidic region [Correira et al., 2008, Ramazzotti et al., 2004] formed at 
the interface with strand a region placed at the protein surface, and 
presumably involved in iron binding [Ramazzotti et al., 2004]. The residues 
Y123 and S161, located in the coils between helix 1 and strand and 
and respectively, are both the last coil residues prior to the next strend. 
Residues W173 and S181 belong to strand and , respectively and S202 
to the turn at the C-terminus. Notably the residues Y123, W173 and S202 are 
mutated in Friedreich‟s ataxia (FRDA) and reported in COSMIC. For each of 
the identified mutant we generated recombinant protein using site-directed 
mutagenesis. With the exception of W173C, all mutations resulted in soluble 
recombinant proteins and allowed us to investigate the results of single amino 
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acid substitution on the hFXN thermal and thermodynamic stability and the 
biological activity. 
 
 
Fig. 4.9 Amino acid sequence and structure of human Frataxin.  A) The mutations 
reported in COSMIC are depicted in bold red, the residues mutated in Friedreich‟s ataxia 
(FRDA) are in bold black and further identified by black dots. Y123, W173 and S202 are 
mutated in FRDA and reported in COSMIC. The black stars represent the residues involved 
in iron binding. The red line highlights the acidic binding region. The secondary structure 
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elements are as reposted in 1EKG [Dhe-Paganon et al, 2000] B) Location of the mutations 
on hFXN structure. Mutated residues are depicted in scaled ball and stick. 
 
4.2.1 Spectroscopic characterization of hFXN 
wild-type and variants 
 
To evaluate the effect of the hFXN variants found in cancer tissues on the 
protein conformation in solution, spectroscopic analysis were performed 
using CD and fluorescence spectroscopy. The spectral contributions of all 
aromatic residues present in hFXN wild-type are evidenced in the near-UV 
CD spectrum that is characterized by an intense negative peak between 260 
and 270 nm and by two other negative contributions at around 285 and 295 
nm (Fig. 4.10A). Most of the variants display near-UV CD spectra almost 
identical to that of the wild-type with slightly differences in the intensity of 
the peaks suggesting that their tertiary structure arrangements are similar to 
that of the corresponding wild-type protein. The most consistent alteration in 
the intensity of the negative contributions are observed in the near-UV CD 
spectrum of Y123S variant that shows a significant decrease of the dichroic 
activity expecially in the region between 265-285 nm, a region where the 
typical spectral contribution of tyrosine is expected. In line with the near-UV 
CD results, the fluorescence emission spectra of variants are similar to that of 
wild-type protein. They show the same maximum emission wavelength 
around 343 nm, with a decreased emission fluorescence intensity (Fig. 
4.10B) with respect to that of the wild-type. 
Far-UV CD spectra of hFXN wild-type and variants show local minima at 
around 208 and 220 nm and a zero intercept at around 200 nm indicating the 
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major contribution of alpha helical secondary structural elements, slightly 
influenced by the contribution of β sheet (Fig. 4.10C). As judged by the 
shape and the intensities of the signals, the secondary structure of the hFXN 
variants is native-like (Fig. 4.10C) suggesting that the effect of the point 
mutations is mainly directed and localized to the mutated residue with minor 
modification of tertiary and secondary arrangements. The 222/208 ellipticity 
ratio gives information about interhelical contacts and is generally used to 
distinguish between coiled coil helices and non-interacting helices (<0.9) 
[Choy N et al,  2003; Kiss RS et al, 2003]. The ratio of the molar ellipticity at 
222 and at 208 nm ([Θ]222/[Θ]208) observed for the wild-type is 0.70 and is 
quite similar for the variants ranging from 0.69 for D104G, to 0.75 for Y123S 
and suggesting that the single amino acid substitutions do not alter 
interhelical interactions in solutions.   
 
Fig. 4.10 Spectroscopic characterization of hFXN wild-type and variants. (A) Near-UV 
CD spectra were recorded in a 1.0-cm quartz cuvette at 1.1-1.3 mg/ml protein concentration 
in 20 mM Tris-HCl pH 8.0 containing 1.0 mM DTT, 1 mM EDTA and 100 mM NaCl. (B) 
Intrinsic fluorescence emission were recorded at 60-80 μg/ml for wild-type and the other 
variants spectra (0.09 AU280nm, 295 nm excitation wavelength), in 20 mM Tris-HCl, pH 
8.0 containing 0.1 M NaCl, 0.1mM EDTA and 0.2 mM DTT. (C) Far-UV CD spectra were 
recorded in a 0.1-cm quartz cuvette at 103-130 g/ml in 20 mM Tris-HCl, pH 8 containing 
0.2 M NaCl and 0.2 mM DTT. All spectra were recorded at 20°C. 
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4.2.2 Thermal and thermodynamic analysis  
 
 The thermal stability of hFXN wild-type and variants was 
investigated by continuously monitoring the ellipticity changes at 222 nm 
between 20 and 95°C in comparison with that of wild-type (Fig. 4.11). By 
monitoring the temperature-induced ellipticity changes at 222 nm, where the 
main amplitude was observed, we observed an apparent cooperative 
transition for hFXN wild-type and all the variants, with apparent Tm values 
ranging from 56.0 to 73.0°C. The thermal unfolding transitions were 
reversible as judged by the signals upon cooling protein solutions to the 
starting temperature. As reported in Table 4.5, a modest increase in Tm value 
was observed for D104G and S202F variants, whereas all the other variants 
show a significant reduction of the Tm values ranging from 3 degrees below 
that of the wild-type, as in the case of A107V, to 14 degrees below that of the 
wild-type, as in the case of Y123S.   
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Fig. 4.11 Thermal unfolding of hFXN wild-type and variants. Normalized [Θ222]; the 
inset shows the first derivative. hFXN wild-type and variants (103 g/ml - 130 g/ml) were 
heated from 20°C to 95°C in 20 mM Tris-HCl, pH 8.0 containing 0.2 M NaCl  and 0.2 mM 
DTT. The molar ellipticity at 222 nm ([Θ222]) was monitored continuously every 0.5 °C.  
 
The impact of point mutations on the thermodynamic stability of hFXN 
was investigated at 20°C in the presence of urea as a chemical denaturant 
agent. hFXN wild-type and variants reversibly unfold in urea in 20 mM 
TrisHCl, pH 8.0, containing 0.1 M NaCl and 200 M DTT with cooperative 
sigmoidal unfolding transitions that follow an apparent two-state model. The 
effect of increasing urea concentrations (0–9 M) on the structure of hFXN 
variants was analyzed by far-UV CD and intrinsic fluorescence emission 
spectroscopy and compared to the wild-type (Fig. 4.12).  
Incubation of hFXN wild-type and variants at increasing urea 
concentrations at 20°C resulted in a progressive change of the intrinsic 
fluorescence emission intensity and a red-shift of the maximal emission 
wavelength. At the end of the transition, above 9 M urea, the intrinsic 
fluorescence emission intensity is increased about 1.5 fold and the maximal 
fluorescence emission wavelength shifts from around 343 nm to around 357 
nm either for the wild-type and all the variants. The intrinsic fluorescence 
emission changes were expressed by calculating the intensity averaged 
emission wavelength λ at increasing urea concentration (Fig. 12B). This 
parameter is an integral measurement, negligibly influenced by the noise, and 
reflects changes in both the shape and the position of the emission spectrum.  
The urea induced unfolding transitions monitored by far-UV CD are 
coincident with those obtained from λ  change (Fig.4.12A). The 
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thermodynamic parameters obtained from the analysis of the far-UV CD and 
fluorescence changes transitions are reported in Table 4.5. D104G and S202F 
show conformational stability very similar to that of the wild-type, whereas 
the difference between the free energy of urea-induced unfolding, ΔGH2O, of  
F109L, Y123S, S161I and S181F variants and that of the wild-type indicates 
a significant decrease in thermodynamic stability of 2–4 kcal∙mol−1 for these 
variants and an increase of about 1 kcal∙mol−1 for A107V variant. The 
changes in m values may indicate differences in the solvent exposed surface 
area upon unfolding between the variants and the wild-type: decrease 
in m values is usually referred to a decrease in the solvent-exposed surface 
area upon unfolding. This is frequently ascribed to an increase in the 
compactness of the residual structure in the non-native state ensemble, rather 
than to an increase of the accessible surface area of the native state [Wrabl J 
et al, 1999; Pradeep L et al, 2004].  
A                                                          B 
 
 
 
 
 
Fig. 4.12 Urea-induced equilibrium unfolding of hFXN wild-type and variants. (A) 
Normalized intensity-averaged emission wavelengthλ). The continuous lines represent the 
nonlinear fitting of the normalizedλ and [Θ222] data to Eq 4. (B) Normalized molar 
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ellipticity at 222 nm ([Θ222]) reported after removal of the high-frequency noise and the low-
frequency random error by SVD. All spectra were recorded at 20 °C. 
 
  ΔG
H
2
O (kcal∙mol−1) m (kcal∙mol−1∙M-1) [Urea]0.5 (M) 
 Tm 
CD 
([ϴ]222) 
Fluorescence 
(Lambda Averaged) 
CD 
([ϴ]222) 
Fluorescence 
(Lambda Averaged) 
CD 
([ϴ]222) 
Fluorescence 
(Lambda Averaged) 
WT 71.0 9.23 ± 0.47 9.77 ± 0.40 1.88 ± 0.10 2.00 ± 0.08 4.91 4.87 
D104G 74.0 9.44 ± 0.46 10.39 ± 0.31 1.82 ± 0.09 1.99 ± 0.06 5.20 5.22 
A107V 68.0 10.03 ± 0.91 9.06 ± 0.22 2.13 ± 0.19 1.95 ± 0.05 4.71 4.64 
F109L 59.6 7.14 ± 0.34 6.18 ± 0.16 2.09 ± 0.10 1.85 ± 0.05 3.42 3.34 
Y123S 56.6 4.31 ± 0.18 4.48 ± 0.18 1.60 ± 0.06 1.59 ± 0.06 2.69 2.84 
S161I 60.0 5.88 ± 0.58 6.95 ± 0.24 1.88 ± 0.19 2.11 ± 0.07 3.12 3.30 
S181F 59.9 6.12 ± 0.27 6.86 ± 0.33 1.84 ± 0.08 1.99 ± 0.09 3.32 3.45 
S202F 70.7 9.07 ±0.32 9.60 ±0.33 1.89 ± 0.07 2.18 ± 0.07 4.78 4.40 
 
Table 4.5 Melting temperatures and thermodynamic parameters for urea-induced 
unfolding equilibrium of hFXN wild-type and variants measured by far-UV CD and 
fluorescence spectroscopy. The temperature-induced changes were followed by monitoring 
the ellipticity at 222 nm. The Tm values were calculated by taking the first derivative of the 
ellipticity at 222 nm with respect to temperature. Urea-induced unfolding equilibrium data 
were measured at 20°C by monitoring ellipticity at 222 nm [Θ222 ] and fluorescence intensity 
averaged emission wavelength λ. G
H
2
O
 and m values were obtained from Eq 3; [Urea]0.5 
was calculated from Eq 5. Data are reported as the mean ± SE of the fit. 
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4.2.3 Analysis of the folding pathway of hFXN 
wild-type and its variants  
  
 In order to better understand the folding of human FXN in its wild-
type form and its variants we resorted to perform kinetic experiments. In an 
effort to fully characterize the folding properties of hFXN and its variants we 
performed stopped-flow kinetic unfolding and refolding experiments, at 
different concentrations of urea ranging from 0M to 8M, in buffer TrisHCl 
50mM, NaCl 100mM, DTT 1mM, pH 8.5, at 37°C. In every experiment 
conducted, the kinetics of folding and unfolding were perfectly described by 
a single exponential behaviour, an aspect that is usually interpreted with the 
absence of stable intermediates accumulating in the ms to s time range. The 
dependences of the logarithm of the observed rate constants versus the 
concentration of urea (chevron plot) for WT is reported in Fig. 4.13. In a 
simple two-state folding mechanism, the resulting chevron plot presents a 
typical V-shape with the logarithm of the observed rate constants of the 
unfolding and refolding arms increasing and decreasing linearly as the 
concentration of urea changes. However, as it might be noted from inspection 
of Fig. 4.13, the arms of the chevron plot of wt hFXN deviate from linearity, 
which suggests the presence of a more complex scenario. In a recent work 
[Bonetti et al., 2014] the folding kinetics of yeast frataxin was extensively 
characterized. The chevron plots obtained for yeast frataxin presented a 
curvature in both the unfolding and refolding arms and were fitted with an 
equation that describes a folding pathway characterized by the presence of a 
broad energy barrier in the transition state [Oliveberg et al., 1998]  
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Thus, we resorted to compare folding kinetics data of the WT human FXN 
with the ones obtained from the yeast FXN, which returned an excellent fit 
(Fig. 4.13). This result suggests that the folding of the human variant of 
hFXN can be described with a comparable mechanism. 
 
Fig. 4.13 Chevron plots of human (black squares) and yeast frataxin (data from Bonetti 
et al 2014) (gray circles). Data are fitted with an equation that takes into account a broad 
energy barrier in the transition state. 
 
Then we performed kinetic folding experiments on the variants of hFXN. The 
resulting chevron plots are reported in Fig. 4.14. A global fit was performed 
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to analyse data, sharing the mu and mf values for all the data sets, which, as 
Fig. 4.14 reports, returned an excellent fit for every variant analysed, 
suggesting that mutations inferred to the protein does not have any effect on 
the folding mechanism of hFXN. Kinetic data obtained from the fit are 
shown in Table 4.6. On the other hand however, some mutations clearly 
affect the stability of hFXN, with the ∆Geq values obtained from kinetics 
being in good agreement with the ones obtained from equilibrium 
fluorescence experiments. 
 
 
 
Fig. 4.14 Chevron plots of the wt hFTX and D104G, A107V, F109L, Y123S, S161I, S181F, 
S202F variants in buffer TrisHCl 50mM, NaCl 100mM, DTT 1mM, pH8.5, at 37°C. A 
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global fit analysis was performed, sharing the mf and mu values for all the data sets (see 
details in the text). 
 
hFXN variant Kf Mf Ku Mu m‟ 
WT 78.5 ± 5.8 1.07 ± 0.05 7.8·10-5 ± 0.8·10-5 2.03 ± 0.09 0.11± 0.01 
D104G 84.5 ± 5.9 1.07 ± 0.05 3.2·10-5 ± 0.3·10-5 2.03 ± 0.09 0.11± 0.01 
A107V 70.0 ± 5.4 1.07 ± 0.05 1.6·10-5 ± 0.2·10-5 2.03 ± 0.09 0.11± 0.01 
F109L 57.7 ± 3.6 1.07 ± 0.05 1.1·10-5 ± 0.1·10-5 2.03 ± 0.09 0.11± 0.01 
Y123S 43.8 ± 2.9 1.07 ± 0.05 3.4·10-5 ± 0.3·10-5 2.03 ± 0.09 0.11± 0.01 
S161F 21.7 ± 1.4 1.07 ± 0.05 1.9·10-5 ± 0.2·10-5 2.03 ± 0.09 0.11± 0.01 
S181F 32.7 ± 2.1 1.07 ± 0.05 3.0·10-5 ± 0.3·10-5 2.03 ± 0.09 0.11± 0.01 
S202F 71.4 ± 4.9 1.07 ± 0.05 9.4·10-5 ± 0.9·10-5 2.03 ± 0.09 0.11± 0.01 
 
Table 4.6 Kinetic data for hFXN WT and variants calculated from chevron plot fitting. 
 
4.3 Biochemical characterization of PARP3 
and analysis of PARP3 nsSNVs  
 
 PARP3 plays an essential role in the maintenance of genome 
integrity. It is known that other proteins of the PARP family, such as PARP1 
and PARP2, are involved in cancer development and tumorigenesis and, 
since they have been described as targets in cancer therapy, a great amount of 
inhibitors have been developed even if they are still not very specific. PARP1 
and PARP2 have been well characterized in the last decades, while the role of 
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PARP3 in tumorigenesis remains largely unknown. Studies in the Françoise 
Dantzer‟s laboratory (CNRS, University of Strasbourg, Strasbourg, France) 
revealed an important role of PARP3 in the control of theTGFβ-induced 
epithelial-to-mesenchymal transition and the acquisition of stem like features 
in breast cancer cells lines [Karicheva O et al, 2016]. These results 
encouraged us to characterize PARP3 in another solid tumor, the 
glioblastoma, which is the most common and aggressive primary brain tumor 
and is resistant to current therapies. It has been described that the protein 
levels of PARP3 are upregulated in primary glioblastoma tissues but 
silencing the expression of PARP3 resulted in a synergistic radiosensitizing 
effect when combined with radiotherapy in glioblastoma cell lines [Quan JJ 
et al, 2015]. However, several questions remain unanswered. The 
transcriptional activity, the catalytic activity, the potential interactors of 
PARP3 have to be analyzed and only a more detailed characterization of the 
biochemical properties of PARP3 could allow us to define this protein as a 
therapeutic target to overcome radioresistance in glioblastoma. In this project 
we use the glioblastoma LN229 cell lines in order to elucidate the molecular 
pathways in which PARP3 could be involved. LN229 PARP3
-/-
 cells have 
been generated using the CRISPR/Cas9 technology. To further verify the role 
of PARP3 activity versus the protein, the LN229 PARP3
-/-
 cells were restored 
for the expression of either an empty vector (Flag), the PARP3 wild-type 
(Flag-PARP3) and a catalytically inactive mutant of PARP3 (Flag-PARP3-
HE). Furthermore, the impact of single amino acid substitution on PARP3 on 
key cellular pathways, such as tumorigenicity and DNA repair, have been 
analyzed and compared with the effect of the mutations on the protein 
structure and stability. 
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4.3.1 PARP3 in the tumorigenicity of 
glioblastoma 
 
In the laboratory of Francoise Dantzer, where I spent a period of my 
PhD, stable PARP3
-/-
 LN229 cell lines were generated using the 
CRISPR/Cas9 method. Next these cells were restored for the expression of 
the PARP3 wild-type (Flag-PARP3-WT), the catalytically inactive PARP3 
(Flag-PARP3-HE) and an empty vector with a Flag tag. The Flag-PARP3-HE 
mutant is a catalytically inactive mutant in which the histidine residue in 
position 384 is mutated in alanine and the glutamate residue in position 514 
is mutated in alanine. 
Human glioblastoma cell lines LN229 (Fig. 4.15A) were maintained 
in Minimum Essential Media (MEM) with 10% fetal bovine serum (FBS) 
and 1% gentamycin (Invitrogen) in a humidified incubator with 37°C and 5% 
CO2. Western blot analysis were performed to verify the expression level of 
the protein after the transfection, antibiotic selection and sorting of the cells. 
We detected high expression of Flag-PARP3 compared to the endogenous 
expression level of the parental PARP3
+/+
 cells (WT), while we observed 
more or less the same expression level of Flag-PARP3-HE respect to that 
observed for PARP3
+/+
. The complementation with Flag showed no 
expression of PARP3 as expected (Fig. 4.15B). 
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Fig. 4.15 A) Representation of adherent LN229 cell line at optical microscope. B) The 
protein Expression levels of PARP3 in the different complemented LN229 PARP3-/- cell 
lines were examined  on nuclear protein extracts prepared as described in Material and 
method and  Western blotting using the appropriate antibodies. For a better illustration 
different amount of protein have been loaded. 40 μg of nuclear protein extract have been 
loaded for the WT and the cells expressing the empty plasmid (Flag). For the Cells 
expressing PARP3 WT and PARP3 HE , respectively 5 μg and 20 μg have been loaded.  
  
Using clonogenic assay we looked at the capacity of the different cells 
lines to proliferate and survive. After performing the experiments in 
triplicate, we could conclude that we didn‟t observe significant differences 
between the wild-type and the other cell lines suggesting that the absence of 
PARP3, the complementation with PARP3 and the complementation with the 
inactive PARP3 mutant do not affect the capacity of LN229 cells to form 
colonies or to proliferate in normal conditions. Knowing the role of PARP3 
in DNA repair, we next aimed to compare the sensitivity of these different 
cell lines to various chemotherapeutics agents (Temozolomide (TMZ), 
Phleomycin (Phleo)) by clonogenic assays. For this, the four LN229 cell lines 
were plated following appropriate dilutions in 6-well-plates and allowed to 
attach overnight. The next day cells were treated for 5 h using three different 
concentrations of the chosen chemotherapeutic agents: 1 µM - 2 µM - 4 µM 
for TMZ, 1 µg/ml - 2 µg/ml -5 µg/ml for Phleo. After 5h the treated cells 
were plated for clonogenic assay. Our pourpose was to evaluate the capacity 
87 
 
of the affected cells to proliferate. After 10 days in a humidified incubator 
with 37°C and 5% CO2 cells were fixed with 5 ml 10% neutral buffered 
formalin solution for 15-30 minutes and stained with 5 ml 0.01% (w/v) 
crystal violet in deuterated water (dH2O) for 30-60 minutes. The crystal 
violet in excess was washed out with dH2O and dishes were allowed to dry. 
Finally digital images of the colonies were obtained using a camera or 
scanning device and colonies were counted using imaging analysis software 
in order to analyze the capacity of the formation of the clones (amount and 
size). Relative to untreated cells, LN229 wild-type treated with the 
chemotherapeutic agents showed a significant reduction in survival and 
proliferation (Fig. 4.16). Indeed, TMZ and Phleo affected the propensity of 
the cells to form clones and above all they affected the proliferation because 
of the significant reduction of the size of the formed clones that is much more 
evident with high concentration of drug. No obvious difference in the number 
or in the size of clones was detected between the different cell lines. We 
conclude that the absence of PARP3 has no significant impact on the survival 
and proliferation efficiency of LN229 cells upon exposure to either TMZ or 
Phleomycin. 
A                                                               B 
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Fig. 4.16 Clonogenicity experiments of the different LN229 cells lines in presence of 
different concentrations of TMZ (A) and Phleo (B). The cells lines have been plated at the 
same dilution range for 10 days and the formed clones were stained using cristal violet. 
Experiments were performed three times. A representative experiment is shown. 
 
 
4.3.2 PARP3 and nsSNVs 
 
 
PARP3, like PARP1 and PARP2, is a DNA-dependent enzyme that is 
catalytically activated upon binding to DNA damage. It shows a typical fold 
that is characterized by a conserved C-terminal region, which contain a WGR 
domain and the CAT domain, and an N-terminal region not conserved 
between members of the PARP family. We focused our attention on the 
WGR and the CAT domains of the protein: WGR domain is responsible for 
the transmission of the information from the DNA damage recognition to the 
CAT site of the protein, and the CAT domain is responsible for the catalytic 
activity of the protein. In the COSMIC database a huge amount of PARP3 
nsSNVs have been reported. We performed a screening of these variants and, 
according to the frequency and to the position of the variants in the 3D 
structure of the protein, we selected F125L, P147T and G148D, located 
respectively in the core and in the flexible loop of the WGR domain (Fig. 
4.17A) and the variants L233F and F440L, located in the CAT domain of 
PARP3 (Fig. 4.17B). 
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A                                                        B 
 
Fig. 4.17 A) Location of the selected variants on PARP3 WGR domain (Pdb code: 2EOC) B) 
Location of the selected variants on PARP3 CAT domain (Pdb code: 4L6Z). 
 
 
We used PARP3 wild-type pET-HPARP-3-Met2 plasmid. Quick Change 
Site-Directed Mutagenesis Kit (Stratagene) was used to introduce the single 
mutations on wild-type hPARP3 plasmid. The presence of the desired 
mutations and the absence of unwanted additional mutations were confirmed 
by plasmid sequencing. 
PARP3 wild-type and the variants were expressed in E. coli strain 
BL21(DE3). 15 ml of overnight culture containing 100 µg/ml ampicillin was 
used to inoculate 500ml LB cultures containing ampicillin as antibiotic at a 
final concentration of 50 µg/ml. Cultures were grown at 37 °C until optical 
density OD600 reached 0.8, the protein expression was induced using 0.5 mM 
isopropyl-β-D-thiogalactoside (Sigma-Aldrich) and cultures were grown at 
18°C overnight with vigorous shaking. The cells were collected by 
centrifugation and the pellet frozen. The first attempts to purify the protein 
were not successful due to technical troubles. 
Several attempts to purify the protein were not successful due to the low 
expression of the protein in soluble form. Cells were resuspended in 35 ml of 
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Binding buffer (20 mM Tris-HCl pH 7.5, 0.5 mM EDTA, 14 mM β-
mercaptoethanol, 0.5 mM PMSF) containing a cocktail of EDTA-free 
protease inhibitors (Sigma-Aldrich) and disrupted by sonication in a 
Vibracell sonicator on ice. The lysate was cleared by centrifugation at 12000 
rpm and the supernatant was applied on a DE52 column (GE Healthcare), 
previously equilibrated with Binding buffer and 0.5 mM tris(2-carboxyethyl)-
phosphine, to remove nucleic acids The flow-through was loaded on a Ni-
NTA (Ni
2+
 - nitriltriacetate) affinity column (GE Healthcare) pre-equilibrated 
with Binding buffer and the protein was eluted using Buffer with 250mM 
Imidazole. Purity and size of the protein was checked by SDS–PAGE on a 4–
12% bis-Tris polyacrylamide gel and by Western blot analysis performed 
using the home-made SE4698 anti-hPARP3 antibody. The signal was 
visualized using ECL-PLUSdetection system (Amersham Biosciences) and 
the images were captured using the Image Quant LAS 4000 imaging system 
(GE Healthcare Life Science). Gels were stained with Coomassie blue R-250.  
Using CD and fluorescence spectroscopy we will perform a detailed 
analysis of the conformation in solution of all PARP3 variants.  
We also decided to analyze the impact of the PARP3 nsSNVs on the viability 
and proliferative capacity of human cancer cells. For this reason we used 
Quick Change Site-Directed Mutagenesis Kit (Stratagene) to obtain the 
PARP3 nsSNVs in the pEGFP vector. MDA MB231 PARP3
-/-
 cells and 
MDA MB436 PARP3
-/-
 breast cancer cells were transfected with an empty 
vector (pEGFP), with the PARP3 wild-type (pEGFPhP3) and with two 
variants of the PARP3 WGR domain (pEGFPhP3-P147T, pEGFPhP3-
G148D) and with one variant of the PARP3 CAT domain (pEGFPhP3-
F440L). 
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The cell culture medium was changed 48 hours after transfection and the 
stable transfectants were selected with neomycin at 500 μg/ml and 250 μg/ml 
in MDA MB231 cells and in MDA MB436 cells respectively. Breast cancer 
cell lines were maintained in RPMI 1640 medium with 10% fetal bovine 
serum (FBS) and 1% gentamycin (Invitrogen) in a humidified incubator with 
37°C and 5% CO2.  
The expression of the variants seems to be toxic for the cells, expecially in 
the case of the variants G148D and F440L in both cell lines (Fig. 4.18). 
 
 
 
Fig. 4.18 Representation of the toxicity of the overexpression of PARP3 wild-type and 
variants in cancer cells A) Control (pEGFP), PARP3 WT (pEGFP hPARP3) and variants 
(pEGFP P147T, pEGFP G148D, pEGFP F440L) overexpressing MDA MB231 cells. B) 
Control (pEGFP), PARP3 WT (pEGFP hPARP3) and variants (pEGFP P147T, pEGFP 
G148D, pEGFP F440L) overexpressing MDA MB436 cells. In both cell lines, the 
overexpression of  pEGFP F440L, a variant of the catalytic region of PARP3, seems to be 
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really toxic for the cells as evidenced by the high mortality and by the changes in the 
morphology of the cells. 
 
Protein extraction and western blot analysis will be performed in order to 
analyze the expression levels of PARP3 wild-type and PARP3 variants. To 
understand the effects of the selected PARP3 variants on cell survival, we 
will evaluate the ability of the transfected cell lines to form colonies in 
clonogenic assays.  
 
4.4 Analysis of the effects induced by single 
amino acid substitution  
 
 The results reported above are framed in a larger project that results 
from their combination with what has been obtained for variants of other 
proteins studied by our group in the last years: Bromodomains (BRDs), 
Peroxisome Proliferator-Activated Receptor  (PPAR), Serine/threonine-
protein kinase pim-1 (Pim-1) and Protein tyrosine phosphatase  (PTP) in 
order to present a detailed evaluation of the possible effects that single amino 
acid substitutions can have on protein structure, function or stability. This 
will be useful to understand how missense variants can influence protein 
properties. We have been interested in nsSNVs that have been found in 
cancer tissues, as reported in COSMIC database [Forbes S.A. et al, 2011], 
OMIM [Hamosh a et al, 2005], Pan-Cancer Atlas (https://www.cell.com/pb-
assets/consortium/pancanceratlas/pancani3/index.html) and SNP database. 
For each protein we chose variants with an high pathogenic score (Table 4.1) 
93 
 
and, after expression and characterization, we classified the selected variants 
according to the observed alterations with respect to the wild-type protein.  
 
4.4.1 Effect on protein conformation in solution 
 
39 of 45 nsSNVs analyzed caused changes in the protein 
conformation in solution. In most of the cases we observed only small 
conformational changes, as evidenced in the near-UV CD spectra of the 
hFXN variants (Fig. 4.10A), for example, suggesting that the tertiary 
structure arrangements of the nsSNVs are really similar to that of the 
corresponding wild-type protein. However, significant differences can also be 
detected, as evidenced in the near-UV CD spectrum of the PGK1 variant 
R65W (Fig. 4.2A) where the substitution of an arginine with a tryptophan 
residue caused a significant alteration in the intensity of the negative peaks in 
the region between 250 and 270nm.  
The most significant example regarding the effect of single amino acid 
substitution on protein conformation in solution in our analyzed dataset of 45 
nsSNVs is represented by the case of E135K variant of Pim-1 considering 
that this missense mutation displayed a near-UV CD spectrum which 
dramatically differed from the wild-type spectrum: the dichroic activity in the 
290–275 nm region is markedly decreased with a positive contribution in the 
region below 275 nm (Fig. 4.19A). These alterations are confirmed by 
fluorescence emission spectroscopy, in particular the fluorescence emission 
spectrum of the variant is centered at the same maximum emission 
wavelength of wild-type at around 345 nm and shows differences in emission 
fluorescence intensity (Fig. 4.19B). Pim-1 is a serine/threonine protein kinase 
[Saris CJ et al, 1991] involved in several signalling pathways such as the 
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regulation of cell cycle progression and apoptosis [Anizon F et al, 2010]. It 
has been identified as a key cofactor regulating the expression of the 
oncogenic transcription factor c-Myc [Zippo A. et al, 2007] and several 
nsSNVs have been reported in prostate cancer and multiple myeloma [Akue´-
Ge´du R. et al, 2009]. Of these variants, E135 is located in helix D and 
forms a hydrogen bond with Q127 which is likely to be important in 
stabilizing this helix (Fig. 4.19C). Furthermore, a significant reduction in the 
protein activity was also observed for this variant: the mutated protein 
showed only about 3% of the activity of the corresponding wild-type. The 
decrease of the activation energy, Ea, detected suggested an increase of the 
flexibility respect to the wild-type counterpart [Lori L et al, PlosOne, 2013]. 
 
 
 
 
 
 
 
 
Fig. 4.19 Location and spectral properties of Pim-1 wild-type and E135K variants (A) 
Near-UV CD spectra The near-UV CD spectrum of wild-type Pim-1 shows the spectral 
contribution of all aromatic residues and is characterized by two strong negative peaks 
centred at 290 nm and at 269 nm accompanied by fine structure features at 275–280 nm (B) 
Intrinsic fluorescence emission spectra. (C) Detailed view of the local structural environment 
around the mutated residue E135. doi:10.1371/journal.pone.0064824.g001 
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4.4.2 Effect on protein structure 
 
7 of 45 nsSNVs analyzed give rise of minimal changes in the protein 
structure as already put in evidence in all the crystal structures of the PGK1 
variants analyzed in this thesis (Fig. 4.5-4.8). 
The mutation of Arg  Leu (R100L) in the ZA loop of the 
Bromodomain 2 domain 1 (BRD2(1)), in close proximity of the acetyl-lysine 
binding site, induced loss of the hydrogen bonds with backbone residues in 
helix αA (Fig. 4.20B) but this did not result in significant structural changes 
[Lori L et al, 2016] (Fig. 4.20A). The Bromodomains (BRDs) are the only 
known protein recognition module that selectively targets ε-N-acetylation of 
lysines. Dysregulation of acetylation levels has been associated with several 
diseases and cancer and inhibitors that specifically target the BRDs can 
interfere with gene expression that mediates cellular growth and evasion of 
apoptosis in cancer. 
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Fig. 4.20 Comparison of the crystal structures of BRD2(1) wild-type and R100L variant 
(A) Superimposition of wild-type BRD2(1) shown as a ribbon diagram with the mutant 
BRD2(1) R100L shown as protein worm in magenta. The mutated residue is shown in ball 
and stick representation and main structural elements are labelled. (B) Details of interactions 
formed by R100 in the wild-type compared to the mutated residue. 
doi:10.1371/journal.pone.0159180.g002 
 
4.4.3 Effect on protein function 
 
27 of 45 nsSNVs analyzed had effect on the protein activity, either 
increasing or decreasing it.  
If a mutation occurs in an active site, it can affect critical components 
of the biological reaction, which, in turn, will alter the normal protein 
function [Stevanin G et al, 2004; Yamada Y et al, 2006]. However, since the 
biochemical reaction is very sensitive to the precise geometry of the active 
sites for both of the reactants and products, not only any conformational 
change altering the active sites can affect the biochemical reaction but also 
mutations that are not expected to perturb protein function by much can do it 
[Takamiya O et al, 2002; Zhang Z et al, 2010; Zhang Z et al, 2011]. 
The effect of non synonymous single nucleotide substitutions on the 
kinetic properties of PGK1 enzyme have already been presented in this thesis 
(Fig. 4.3 and Table 4.2) by putting in evidence a reduced catalytic efficiency 
for most of the variants with the exception of F241S that displays a two fold 
increase of activity. 
An interesting example about changes on the protein activity due to 
the presence of missense mutations is represented by the case of Protein 
tyrosine phosphatase  (PTP) (PDB code 2OOQ). In particular,  PTPloses 
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detectable enzymatic activity due to a D927G mutation that has been found in 
cancer tissue (Fig. 4.21A,B). PTPbelongs to the classical receptor type IIB 
family of protein tyrosine phosphatase and several evidences suggest that it 
acts as a tumour suppressor gene [Wang Z et al, 2004]. PTP missense 
variants have been identified in human cancer tissues. The mutation D927G 
involves a solvent exposed residue (Asp-927) placed in a 4 residues turn 
between two coils and distant from the catalytic site of the enzyme. It 
connects different protein secondary structure regions through hydrogen 
bonds with three residues (Asp-947, Lys-930 and Glu-931) (Fig. 4.22C). 
Presumably, the change in main chain flexibility caused by the high 
destabilizing D927G mutation may lead to local disorder and may affect the 
stabilizing hydrogen bonds of residues in close proximity [Pasquo A et al, 
2012]. 
 
 
Fig. 4.21 Effect of temperature on phosphatase activity of PTP wild-type and mutants 
and location of PTP mutations. (A) Temperature dependence of phosphatase activity of 
PTP wild-type and mutants. (B) Non-linear fit of the temperature dependence of 
phosphatase activity to the Arrhenius equation; the inset shows the linear Arrhenius plot for 
the same data. doi:10.1371/journal.pone.0032555.g004 (C) Local environment of D927. 
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4.4.4 Effect on protein binding 
 
A nsSNV can alter the binding site of the protein, can change the 
interactions with partners (activators, repressors or substrates) and can also 
affect the kinetics of interactions with partner or the binding specificity 
[Kohler et al, 2008; Wu et al, 2008; Bauer-Mehren et al, 2009; Vanunu et al, 
2010; Barabàsi et al, 2011].  
If a missense mutation occurs on a residue located in the binding 
interface, crucial in contributing to the interaction [Dixit A et al, 2009; 
Ozbabacan SEA et al, 2010], the binding affinity would be dramatically 
affected due to geometrical constrains and/or energetic effects [Akhavan S et 
al, 2005; Jones R et al, 2007]. For instance, when substituting a small side 
chain for a bulky side chain in a narrow binding pocket, the entrance of the 
partner group will be blocked and the binding process will be completely or 
partially prevented [Rignall TR et al, 2002; Zhang Z et al, 2011]. 
26 of 45 nsSNVs analyzed induced changes in the binding properties 
of the protein. One interesting example is represented by the case of the 
H395R variant of the Bromodomain 3 domain 2 (BRD3(2)). The substitution 
of the histidine residue in position 395 of the (BRD3(2)) with an arginine 
residue decreased of more than two-fold the Kd for the thienodiazepine JQ1 
(Kd wild-type 23.4 ± 1.3 nM, Kd H395R 7.0 ± 0.4 nM) and increased of about 
nine-fold the Kd for the quinazolinone PFI-1 (Kd wild-type 161.0 ± 5.9, Kd 
H395R 1386.0 ± 65.0 nM), two inhibitors of pharmacological interest, as 
demonstrated by ITC experiments that put in evidence a significant alteration 
in binding enthalpy and binding affinity [Lori L et al, 2016] (Fig. 4.22C). By 
comparing the crystal structure of BRD3(2) wild-type with JQ1 and the 
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structure of BRD3(2) H395R we observed that the arginine residue 
introduced by this point mutation may form a more favourable hydrogen 
bond with the carbonyl oxygen of the ester link [Lori L et al, 2016] (Fig. 
4.22A,B) 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.22 Binding of BRD3(2) H395R variant to inhibitors (A) Structure of BRD3(2) 
H395R variant. The mutated residues are highlighted. A nitrate molecule, present in the 
crystallization solution occupied the acetyl-lysine binding site in BRD3(2) H395R. The 
conserved asparagine (N391) formed canonical hydrogen bonds with the nitrated ion. (B) 
Superimposition of the wild-type JQ1 complex with BRD3(2) H395R (C) ITC experiments 
measuring the interaction of the panBET inhibitor JQ1 with wild-type BRD3(2) (black 
curve) and BRD3(2) H395R (blue curve). Shown are raw titration heats (top panel) as well 
as normalized binding enthalpies as a function of ligand/protein ratio (lower panel). The best 
fit to a single binding site model is shown as solid lines. (D) ITC experiments showing the 
100 
 
binding of the pan-BET inhibitor PFI-1 with BRD3(2) and the H395R variant. 
doi:10.1371/journal.pone.0159180.g004. 
 
 
4.4.5 Effect on protein stability 
 
 33 of 45 nsSNVs analyzed showed a reduction of the protein stability, 
as evident from the analysis of the thermodynamic parameters of the variants 
of PGK1 and hFXN reported in this thesis (Table 4.4 and 4.5) that point to a 
destabilization of the native state indicated by the decrease of GH2
O
 values 
for most of the variants.  
Protein stability is also a key characteristic of a functional protein [Capriotti 
E et al, 2005; Ye Y et al, 2006; Zhan Z et al, 2010; Zhang Z et al, 2011]. 
It is known that a single base DNA variant results in alteration of stability of 
the corresponding native protein [Wang and Moult, 2001; Yue et al, 2005] 
and that about 80% of missense mutations associated with disease affects the 
stability of proteins by several kcal∙mol−1 [Wang and Moult, 2001]. A nsSNV 
can have destabilizing or stabilizing effects: most frequently, missense 
mutations lead to a destabilization of the protein stability by making it 
susceptible to proteolysis or by changing the thermal inactivation temperature 
[Pasquo A et al, 2012; Lori L et al, 2013] or by affecting protein folding and 
producing changes in thermodynamic stability [Adhikari et al, 2015; Kroncke 
et al, 2015; Petrosino M et al, 2017].  
The variant E140K of BRD2(1) decreases drastically the thermal and the 
thermodynamic stability of the protein. The thermal stability of the wild-type 
and of the variant was investigated by continuously monitoring the molar 
ellipticity changes at 222nm between 20 and 80°C and the substitution of 
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Glu140 with Lys induced a significant decrease in the melting temperature 
(Tm): the Tm determined for E140K (44°C), calculated by plotting the first 
derivative of the molar ellipticity at 222nm as a function of temperature, is 
about 10 degree below the Tm of the wild-type protein (54.8°C) (Fig. 4.23A) 
[Lori L et al, 2016]. 
 
Fig. 4.23 Thermal unfolding transition and urea-induced equilibrium unfolding of 
BRD2(1) wild-type and E140K variant (A) Wild-type (black) and E140K variant (cyan) 
were heated between 20 and 80°C in a 0.1-cm quartz cuvette at 0.2mg/ml. The insert shows 
the first derivative of the same data. (B) Normalized molar ellipticity at 222nm reported after 
removal of the high-frequency noise and the low-frequency random error.
 
The lower Tm value and the high loss of secondary structure elements upon 
unfolding suggest that the point mutation induces a remarkable 
destabilization of the native state of BRD2(1). Studying the thermodynamic 
stability by urea-induced unfolding experiments, a decrease in the free-
energy GH2
O
 was also detected (Fig. 4.23B). E140 is a solvent exposed 
residue located in the B helix and does not participate in any other 
interactions with another helix but is involved in stabilizing contacts with the 
amino acid residues in the close coil.  
A B 
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4.4.6 Effect of single amino acid substitution on 
protein production 
 
Several mutations can affect the production of protein, most probably 
reflecting their influence on folding efficiency, generally decreasing the 
probability of the protein reaching its active conformation.  
2 of 45 nsSNVs analyzed could not be expressed in soluble fraction 
even when different growth and induction conditions were used. This is the 
case of  W173C variant of hFXN (Fig. 4.9) and E324K variant of the 
Peroxisome Proliferator-Activated Receptor  (PPAR. PPAR, a nuclear 
receptor that belongs to the superfamily of ligand inducible transcription 
factors, is involved in several biological processes and in the maintenance of 
cellular homeostasis [Sauer S, 2015] and several nsSNVs have been found in 
cancer tissues [Kersten S et al, 2000; Wang T et al, 2006; Lehrke M et al, 
2005; Spiegelman BM et al, 2008]. Mapping of this mutation onto the 
structure of PPARγ revealed that E324 is involved (with R397) in one of the 
two salt bridges that play a pivotal role in the domain stabilization (Fig. 4.24) 
[Petrosino M et al, 2017]. 
 
 
 
 
 
Fig. 4.24 Local environment of residue E324 involved in one salt bridge. 
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Chapter 5 
 
Discussion 
 
Single nucleotide substitution in DNA that alters an amino acid in the 
corresponding codon (non synonymous change) generates a mutant protein 
(nsSNV) with possible structural or functional alterations. A high percentage 
of nsSNVs have been found in different cancer types and catalogued in 
several databases, such as COSMIC [Forbes et al, 2010] or Pan-Cancer Atlas 
(https://www.cell.com/pb-
assets/consortium/pancanceratlas/pancani3/index.html), suggesting that the 
change of an amino acid is an event that could be crucial for cellular 
transformation. The resulting variant carrying the missense mutation may 
initiate the cascade of downstream signalling and eventually transforms the 
cellular phenotype from normal to malignant. However, a point mutation may 
still affect the structure and function of the protein not causing a disease. 
In this thesis a biochemical characterization of nsSNVs that have been 
detected in different types of cancer has been performed in order to 
investigate the effect of missense substitutions on the nsSNV structure, 
function or stability. In particular, we studied variants of three proteins 
involved in the regulation of cell metabolism (PGK1, hFXN) and in the 
response of DNA damages (PARP3). The results obtained for these variants 
have been combined with those obtained for variants found in cancer tissues 
of other proteins studied by our group in the last years (BRDs [Lori L et al, 
2016], PPAR [Petrosino M et al, 2017], Pim-1 [Lori C et al, 2013] and PTP 
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[Pasquo A et al, 2012] in order to present a detailed evaluation of properties 
of protein variants caused by single amino acid substitutions. The data 
reported here provide an important contribution to fill the gap between the 
collection of thermodynamic data and disease-related information on protein 
variants.  
Our analysis of a dataset of 45 nsSNVs (Table 4.1) underscores that 
the single amino acid substitutions can affect the properties of the native 
protein in different ways. They usually influence the protein conformation 
and the protein stability and in several cases it was possible to detect 
alteration of the protein function and of the binding properties.   
Most of the variants studied show significantly alterations of their 
tertiary interactions, as indicated by the differences in their near-UV CD fine 
structure and/or in the ellipticity amplitude, when compared to the 
corresponding wild-type proteins (Fig. 4.2A, 4.10A, 4.19A). The changes in 
tertiary arrangements of most of the variants were also evident from their 
intrinsic fluorescence spectra that showed differences in relative intensity 
and/or in the maximum emission wavelength (Fig. 4.2B, 4.10B, 4.19B). Due 
to the usually surface exposed location of the mutated residues (69% solvent 
exposed, 31% buried) (Fig. 3.1), the consequences of the mutations were not 
obvious. 
The structures of some of the variants that showed the most 
significant changes in their thermodynamics or functional properties were 
determined by X-ray crystallography. Notably, the structural comparative 
analysis shows that the introduced mutations do not cause large 
conformational changes in the protein tridimensional structure but only local 
changes involving the mutated residues and their chemical surrounding (Fig. 
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4.5-4.8, 4.20, 4.22). These local changes may be responsible for local 
differences in protein flexibility. 
Amino acid substitutions altering the structure or the conformational 
rearrangement in solution of the native protein could remarkably affect the 
network of protein interactions, above all when the substitution involves a 
solvent exposed residue. These alterations may lead to change in the 
interactions with ligands or inhibitors as reported for the BRD3(2) H395R 
variant in which the significant differences observed in the near-UV CD 
spectrum, that indicate that its tertiary structure arrangements is different 
from that of its wild-type counterpart, have been associated with a significant 
reduction in the binding enthalpy and in the binding affinity for JQ1 and PFI-
1 (Fig. 4.22) [Lori L et al, 2016]. 
The global effects of local alterations are evident from the analysis of 
the thermodynamic parameters that point to a remarkable destabilization of 
the native state, as suggested by the significant changes in both thermal and 
thermodynamic stability resulting in changes in Tm and/or inG
H
2
O
 values in 
most of the 45 analyzed variants (Fig. 4.23 and Table 4.4, 4.5). Protein 
stability is a key characteristic of a functional protein [Wang and Moult 2001; 
Zhang et al, 2001; Capriotti et al, 2005] and its evaluation could help to 
predict the half-life of the mutant proteins. 
Independently from the position of the mutation on the protein, one of 
the result of the amino acid substitutions, object of this report, is a significant 
change in the variants catalytic properties, in fact most of the variants display 
an altered catalytic efficiency. This is particularly evident for the PGK1 
variant R38M, that shows a decrease of eight order of magnitude of the 
kcat/KM value, mainly due to a dramatic decrease of the turnover number 
(Table 4.2) [Fiorillo A et al, 2018]. As shown in the structure (Fig. 4.3), R38 
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is located in the 3-PG binding site and interacts electrostatically with the 
carboxyl group of 3-PG, hence it is critical for the positioning of the substrate 
in the catalytic site and for the stabilization of the transition state. 
Accordingly, the substitution of the R38 implies a dramatic decrease of the 
kcat and an increase of KM. Given that PGK1 is a glycolytic enzyme, the 
reduced catalytic properties of PGK1 variants may suggest that their 
expression in the neoplastic cells would significantly burden the metabolic 
flux through the glycolytic pathway. Thus, metabolic intermediates may 
accumulate and be converted in other products through alternative pathway, 
such as the pentose shunt, that could supply for the biosynthetic need of the 
growing and proliferating tumour cell. On the other hand, the occurrence of a 
“glycolytic jam” may induce the cell to increase the uptake of glucose. 
 In conclusion, our data give a comprehensive understanding of three-
dimensional structure, dynamics, and biophysics of wild-type and nsSNVs 
that can be used to develop better tools for accurate predictions regarding the 
consequences of single amino acid changes. Since the integration of 
information from multiple heterogeneous sources including sequence, 
structural data and cellular pathway analysis can help to understand the 
molecular basis of cancer, our future perspective is represented by the study 
of the impact of the selected nsSNVs on important pathways for the cell, such 
as cellular differentiation, apoptosis and propensity to tumorigenicity. This 
purpose is at the beginning for the PARP3 variants and we aim to extend this 
kind of analysis to all the 45 nsSNVs analyzed in this study from a 
biochemical point of view in order to test how these variants can modulate 
the efficiency of the cellular pathways of the protein. 
Thanks to the useful information that can be provided from a detailed 
investigation at the molecular and cellular level of the protein variants 
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carrying missense mutations, the development of new therapeutic strategies 
could be possible, expecially in the search of small molecules able to 
selectively interact with the variants, which is an essential preliminary step to 
personalized medicine. Furthermore, since we might expect that some 
nsSNVs will modulate the output of the cellular pathways of the protein by 
making them more or less efficient, research over the next few years will 
likely uncover this gap in the study of nsSNVs and it will make treatment of 
cancer more successful. 
 
 
 
 
 
 
 
 
 
 
 
108 
 
109 
 
Chapter 6 
Attachments 
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Common acronyms and abbreviations 
AD                                 Alzheimer‟s disease 
ALS                               Amyotrophic lateral sclerosis 
ART                              ADP-rybosyl transferase 
ARTD                            Diphteria-toxin-like ADP-rybosyl transferase 
ATP                               Adenosine triphosphate 
BER/SSBR                    Base excision repair/single strand break repair 
BLI                                BioLayer Interferometry 
1,3-BPG                        1,3-Bisphosphoglycerate 
BRD                               Bromodomain 
CAT                               C-terminal catalytic domain 
CD                                  Circular dichroism 
COSMIC                       Catalogue Of Somatic Mutation In Cancer 
dbSNP                           Single Nucleotide Polymorphism Database 
G                                 Gibbs free energy 
DTT                               Dithiothreitol 
Ea
aǂ                 
                      Activation energy 
EDTA                            Ethylenediaminetetraacetic acid 
EMT                              Epithelial–mesenchymal transition 
ERK1/2                         Extracellular signal–regulated kinases 1/2 
FBS                                Fetal Seurm Bovine 
FRDA                            Friedreich Ataxia 
FXN                               Frataxin 
GOF                               Gain of function 
GWAS                           Genome-wide association studies 
HapMap                        The International HapMap Project 
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HD                                 Huntington‟s disease 
hFXN                             human Frataxin 
HGV                              Human Genome Variation 
HIF-1                    Hypoxia-inducible factor 1-alpha 
HIF-2                    Hypoxia-inducible factor 2-alpha 
IPTG                             Isopropil-β-D-1-tiogalattopiranoside 
ISC                                Iron-sulfur cluster 
Isd11                             Nfs1 interacting protein 
Isu                                 Iron-sulfur cluster assembly scaffold protein                                 
ITC                                Isothermal titration calorimetry 
LBD                               Ligand Binding Domain 
LOF                               Loss of function 
MD                                Molecular dynamics 
MATLAB                      Matrix Laboratory 
MEM                             Minimal Essential Medium 
MgADP                         Adenosine 5′-diphosphate magnesium salt 
MgATP                         Adenosine 5′-triphosphate magnesium salt 
NaCl                              Sodium chloride 
NCI                                National Cancer Institute 
Nfs1                                Cysteine desulfurase 
NHEJ                             Nonhomologous end-joining 
NHGRI                          National Human Genome Research Institute 
nsSNV                            Non synonymous Single Nucleotide Variant 
NTR                               N-terminal region 
OD600                             Optical density 
OMIM                           Online Mendelian Inheritance in Man 
PARP                             Poly (ADP-ribose) polymerase 
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PD                                  Parkinson‟s disease 
PDB                                Protein Data Bank 
PDHK1                          Pyruvate dehydrogenase (acetyl-transferring)] kinase  
                                        isozyme 1 
3-PG                               3-Phosphoglycerate 
PGK1                             Phosphoglycerate kinase 1 
Phleo                               Phleomycin 
Pim-1                              Serine/threonine-protein kinase pim-1   
PPARPeroxisome proliferator-activated receptor gamma 
PTPProtein tyrosine phosphatase  
ROS                                Reactive oxygen species 
SF                                   Stopped-flow 
SNP                                Single Nucleotide Polymorphism 
SNV                               Single Nucleotide Variant 
SVD                               Singular Value Decomposition 
TARGET                      Therapeutically Applicable Research to Generate                   
                                       Effective Treatments 
TCGA                           The Cancer Genome Atlas 
TCEP                            Tris(2-carboxyethyl)phosphine hydrochloride 
TGF                            Transforming growth factor beta 
Tm                                  Melting Temperature 
TMZ                              Temozolomide 
Tris/HCl                        Tris(hydroxymethyl)aminomethane hydrochloride 
UniProt                          Universal Protein 
WGR                             Tryptophan-glycine-arginine 
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